TY 2019 Form 990

(A) Name and title	(B) Average hours per week (list any hours for related organizations below dotted line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)	(E) Reportable compensation from related organizations (W-2/1099-MISC)
(1) RICHARD W BROWN...................................................................... DIRECTOR/CHAIR	2.0 ................. 46.0	X	X		0	2,543,498	61,830
(2) RODERICK L STURGEON...................................................................... DIRECTOR/CFO	2.0 ................. 48.0	X	X		0	1,704,983	64,605
(3) DAVID A WELTE...................................................................... DIRECTOR/SECRETARY	2.0 ................. 48.0	X	X		0	1,425,034	70,740
(4) DAVID M CHAO...................................................................... DIRECTOR/PRESIDENT/CEO	40.0 ................. 4.0	X	X		1,370,171	0	43,446
(5) ROBERT E KRUMLAUF - T...................................................................... DIR/SCIENTIFIC DIR EMERITUS	40.0 ................. 4.0	X			631,407	0	63,105
(6) BRENT KREIDER...................................................................... CHIEF OPERATING OFFICER	2.0 ................. 40.0		X		0	616,652	25,223
(7) R SCOTT HAWLEY...................................................................... INVESTIGATOR	40.0 ................. 2.0			X	372,647	0	61,908
(8) JERRY L WORKMAN...................................................................... INVESTIGATOR	40.0 ................. 0.0			X	373,543	0	54,043
(9) JOAN W CONAWAY...................................................................... INVESTIGATOR	40.0 ................. 0.0			X	311,126	0	61,863
(10) RONALD C CONAWAY...................................................................... INVESTIGATOR	40.0 ................. 0.0			X	313,193	0	43,446
(11) LINHENG LI...................................................................... INVESTIGATOR	40.0 ................. 0.0			X	276,038	0	42,317
(12) ALEJANDRO SANCHEZ ALVA...................................................................... DIR/SCIENTIFIC DIR FROM 7/2019	40.0 ................. 4.0	X			154,210	0	16,751
(13) VIRGINIA G STOWERS...................................................................... DIRECTOR	2.0 ................. 2.0	X			0	0	0
(14) ALBERZINE FREEMAN...................................................................... DIRECTOR	2.0 ................. 4.0	X			0	0	0
(15) JONATHAN THOMAS...................................................................... DIRECTOR	2.0 ................. 4.0	X			0	0	0

- TIN:

SCHEDULE A
(Form 990 or 990EZ)

Department of the Treasury
Internal Revenue Service

Public Charity Status and Public Support

Complete if the organization is a section 501(c)(3) organization or a section 4947(a)(1) nonexempt charitable trust.
right arrow

Attach to Form 990 or Form 990-EZ.
right arrow

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2019

Open to Public
Inspection

Name of the organization

STOWERS INSTITUTE FOR MEDICAL RESEARCH

Employer identification number

20-2993509

Part I

Reason for Public Charity Status (All organizations must complete this part.) See instructions.

The organization is not a private foundation because it is: (For lines 1 through 12, check only one box.)

A church, convention of churches, or association of churches described in section 170(b)(1)(A)(i).

A school described in section 170(b)(1)(A)(ii). (Attach Schedule E (Form 990 or 990-EZ).)

A hospital or a cooperative hospital service organization described in section 170(b)(1)(A)(iii).

A medical research organization operated in conjunction with a hospital described in section 170(b)(1)(A)(iii). Enter the hospital's name, city, and state:

SEE SCHEDULE A

PART VI

An organization operated for the benefit of a college or university owned or operated by a governmental unit described in section 170(b)(1)(A)(iv). (Complete Part II.)

A federal, state, or local government or governmental unit described in section 170(b)(1)(A)(v).

An organization that normally receives a substantial part of its support from a governmental unit or from the general public described in section 170(b)(1)(A)(vi). (Complete Part II.)

A community trust described in section 170(b)(1)(A)(vi). (Complete Part II.)

An agricultural research organization described in 170(b)(1)(A)(ix) operated in conjunction with a land-grant college or university or a non-land grant college of agriculture. See instructions. Enter the name, city, and state of the college or university:

An organization that normally receives: (1) more than 331/3% of its support from contributions, membership fees, and gross receipts from activities related to its exempt functions—subject to certain exceptions, and (2) no more than 331/3% of its support from gross investment income and unrelated business taxable income (less section 511 tax) from businesses acquired by the organization after June 30, 1975. See section 509(a)(2). (Complete Part III.)

An organization organized and operated exclusively to test for public safety. See section 509(a)(4).

An organization organized and operated exclusively for the benefit of, to perform the functions of, or to carry out the purposes of one or more publicly supported organizations described in section 509(a)(1) or section 509(a)(2). See section 509(a)(3). Check the box in lines 12a through 12d that describes the type of supporting organization and complete lines 12e, 12f, and 12g.

Type I. A supporting organization operated, supervised, or controlled by its supported organization(s), typically by giving the supported organization(s) the power to regularly appoint or elect a majority of the directors or trustees of the supporting organization. You must complete Part IV, Sections A and B.

Type II. A supporting organization supervised or controlled in connection with its supported organization(s), by having control or management of the supporting organization vested in the same persons that control or manage the supported organization(s). You must complete Part IV, Sections A and C.

Type III functionally integrated. A supporting organization operated in connection with, and functionally integrated with, its supported organization(s) (see instructions). You must complete Part IV, Sections A, D, and E.

Type III non-functionally integrated. A supporting organization operated in connection with its supported organization(s) that is not functionally integrated. The organization generally must satisfy a distribution requirement and an attentiveness requirement (see instructions). You must complete Part IV, Sections A and D, and Part V.

Check this box if the organization received a written determination from the IRS that it is a Type I, Type II, Type III functionally integrated, or Type III non-functionally integrated supporting organization.

Enter the number of supported organizations ...............................

Provide the following information about the supported organization(s).

(i) Name of supported organization	(ii) EIN	(iv) Is the organization listed in your governing document?		(v) Amount of monetary support (see instructions)	(vi) Amount of other support (see instructions)
(i) Name of supported organization	(ii) EIN	Yes	No	(v) Amount of monetary support (see instructions)	(vi) Amount of other support (see instructions)


Total

For Paperwork Reduction Act Notice, see the Instructions for
Form 990 or 990-EZ.

Cat. No. 11285F

Schedule A (Form 990 or 990-EZ) 2019

Page 2

Part II

Support Schedule for Organizations Described in Sections 170(b)(1)(A)(iv) and 170(b)(1)(A)(vi)
(Complete only if you checked the box on line 5, 7, or 8 of Part I or if the organization failed to qualify under Part III. If the organization failed to qualify under the tests listed below, please complete Part III.)

Section A. Public Support

Calendar year (or fiscal year beginning in)		(a) 2015	(b) 2016	(c) 2017	(d) 2018	(e) 2019	(f) Total
1	Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") ..
2	Tax revenues levied for the organization's benefit and either paid to or expended on its behalf....
3	The value of services or facilities furnished by a governmental unit to the organization without charge..
4	Total. Add lines 1 through 3
5	The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f)..
6	Public support. Subtract line 5 from line 4.

Section B. Total Support

Calendar year (or fiscal year beginning in)		(a) 2015	(b) 2016	(c) 2017	(d) 2018	(e) 2019	(f) Total
7	Amounts from line 4..
8	Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources...
9	Net income from unrelated business activities, whether or not the business is regularly carried on..
10	Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.)..
11	Total support. Add lines 7 through 10

Gross receipts from related activities, etc. (see instructions) ..................

First five years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization, check this box and stop here........................................ right arrow

Section C. Computation of Public Support Percentage

Public support percentage for 2019 (line 6, column (f) divided by line 11, column (f)) .........

Public support percentage for 2018 Schedule A, Part II, line 14 ...............

16a

33 1/3% support test—2019. If the organization did not check the box on line 13, and line 14 is 33 1/3% or more, check this box
and stop here. The organization qualifies as a publicly supported organization ....................... right arrow

33 1/3% support test—2018. If the organization did not check a box on line 13 or 16a, and line 15 is 33 1/3% or more, check this
box and stop here. The organization qualifies as a publicly supported organization ..................... right arrow

17a

10%-facts-and-circumstances test—2019. If the organization did not check a box on line 13, 16a, or 16b, and line 14
is 10% or more, and if the organization meets the "facts-and-circumstances" test, check this box and stop here. Explain
in Part VI how the organization meets the "facts-and-circumstances" test. The organization qualifies as a publicly supported
organization ..................................................... right arrow

10%-facts-and-circumstances test—2018. If the organization did not check a box on line 13, 16a, 16b, or 17a, and line
15 is 10% or more, and if the organization meets the "facts-and-circumstances" test, check this box and stop here.
Explain in Part VI how the organization meets the "facts-and-circumstances" test. The organization qualifies as a publicly
supported organization ................................................ right arrow

Private foundation. If the organization did not check a box on line 13, 16a, 16b, 17a, or 17b, check this box and see
instructions ..................................................... right arrow

Schedule A (Form 990 or 990-EZ) 2019

Page 3

Part III

Support Schedule for Organizations Described in Section 509(a)(2)
(Complete only if you checked the box on line 10 of Part I or if the organization failed to qualify under Part II. If the organization fails to qualify under the tests listed below, please complete Part II.)

Section A. Public Support

Calendar year (or fiscal year beginning in)		(a) 2015	(b) 2016	(c) 2017	(d) 2018	(e) 2019	(f) Total
1	Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") .
2	Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose
3	Gross receipts from activities that are not an unrelated trade or business under section 513 .....
4	Tax revenues levied for the organization's benefit and either paid to or expended on its behalf...
5	The value of services or facilities furnished by a governmental unit to the organization without charge
6	Total. Add lines 1 through 5
7a	Amounts included on lines 1, 2, and 3 received from disqualified persons
b	Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year.
c	Add lines 7a and 7b..
8	Public support. (Subtract line 7c from line 6.)

Section B. Total Support

Calendar year (or fiscal year beginning in)		(a) 2015	(b) 2016	(c) 2017	(d) 2018	(e) 2019	(f) Total
9	Amounts from line 6...
10a	Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources..
b	Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975.
c	Add lines 10a and 10b.
11	Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on.
12	Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) ..
13	Total support. (Add lines 9, 10c, 11, and 12.)..

First five years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization,
check this box and stop here............................................. right arrow

Section C. Computation of Public Support Percentage

Public support percentage for 2019 (line 8, column (f) divided by line 13, column (f)) .........

Public support percentage from 2018 Schedule A, Part III, line 15 ...............

Section D. Computation of Investment Income Percentage

Investment income percentage for 2019 (line 10c, column (f) divided by line 13, column (f)) ......

Investment income percentage from 2018 Schedule A, Part III, line 17 .............

19a

331/3% support tests—2019. If the organization did not check the box on line 14, and line 15 is more than 33 1/3%, and line 17 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization ....... right arrow

33 1/3% support tests—2018. If the organization did not check a box on line 14 or line 19a, and line 16 is more than 33 1/3% and line 18 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization .... right arrow

Private foundation. If the organization did not check a box on line 14, 19a, or 19b, check this box and see instructions .... right arrow

Schedule A (Form 990 or 990-EZ) 2019

Page 4

Part IV

Supporting Organizations

(Complete only if you checked a box on line 12 of Part I. If you checked 12a of Part I, complete Sections A and B. If you checked 12b of Part I, complete Sections A and C. If you checked 12c of Part I, complete Sections A, D, and E. If you checked 12d of Part I, complete Sections A and D, and complete Part V.)

Section A. All Supporting Organizations

Yes

Are all of the organization’s supported organizations listed by name in the organization’s governing documents?
If "No," describe in Part VI how the supported organizations are designated. If designated by class or purpose,
describe the designation. If historic and continuing relationship, explain.

Did the organization have any supported organization that does not have an IRS determination of status under section 509(a)(1) or (2)? If "Yes," explain in Part VI how the organization determined that the supported organization was described in section 509(a)(1) or (2).

Did the organization have a supported organization described in section 501(c)(4), (5), or (6)? If "Yes," answer (b) and (c) below.

Did the organization confirm that each supported organization qualified under section 501(c)(4), (5), or (6) and satisfied the public support tests under section 509(a)(2)? If "Yes," describe in Part VI when and how the organization made the determination.

Did the organization ensure that all support to such organizations was used exclusively for section 170(c)(2)(B) purposes? If "Yes," explain in Part VI what controls the organization put in place to ensure such use.

Was any supported organization not organized in the United States ("foreign supported organization")? If “Yes” and if you checked 12a or 12b in Part I, answer (b) and (c) below.

Did the organization have ultimate control and discretion in deciding whether to make grants to the foreign supported organization? If “Yes,” describe in Part VI how the organization had such control and discretion despite being controlled or supervised by or in connection with its supported organizations.

Did the organization support any foreign supported organization that does not have an IRS determination under sections 501(c)(3) and 509(a)(1) or (2)? If “Yes,” explain in Part VI what controls the organization used to ensure that all support to the foreign supported organization was used exclusively for section 170(c)(2)(B) purposes.

Did the organization add, substitute, or remove any supported organizations during the tax year? If “Yes,” answer (b) and (c) below (if applicable). Also, provide detail in Part VI, including (i) the names and EIN numbers of the supported organizations added, substituted, or removed; (ii) the reasons for each such action; (iii) the authority under the organization's organizing document authorizing such action; and (iv) how the action was accomplished (such as by amendment to the organizing document).

Type I or Type II only. Was any added or substituted supported organization part of a class already designated in the organization's organizing document?

Substitutions only. Was the substitution the result of an event beyond the organization's control?

Did the organization provide support (whether in the form of grants or the provision of services or facilities) to anyone other than (i) its supported organizations, (ii) individuals that are part of the charitable class benefited by one or more of its supported organizations, or (iii) other supporting organizations that also support or benefit one or more of the filing organization’s supported organizations? If “Yes,” provide detail in Part VI.

Did the organization provide a grant, loan, compensation, or other similar payment to a substantial contributor (defined in section 4958(c)(3)(C)), a family member of a substantial contributor, or a 35% controlled entity with regard to a substantial contributor? If “Yes,” complete Part I of Schedule L (Form 990 or 990-EZ) .

Did the organization make a loan to a disqualified person (as defined in section 4958) not described in line 7? If “Yes,” complete Part I of Schedule L (Form 990 or 990-EZ).

Was the organization controlled directly or indirectly at any time during the tax year by one or more disqualified persons as defined in section 4946 (other than foundation managers and organizations described in section 509(a)(1) or (2))? If “Yes,” provide detail in Part VI.

Did one or more disqualified persons (as defined in line 9a) hold a controlling interest in any entity in which the supporting organization had an interest? If “Yes,” provide detail in Part VI.

Did a disqualified person (as defined in line 9a) have an ownership interest in, or derive any personal benefit from, assets in which the supporting organization also had an interest? If “Yes,” provide detail in Part VI.

10a

Was the organization subject to the excess business holdings rules of section 4943 because of section 4943(f) (regarding certain Type II supporting organizations, and all Type III non-functionally integrated supporting organizations)? If “Yes,” answer line 10b below.

10a

Did the organization have any excess business holdings in the tax year? (Use Schedule C, Form 4720, to determine whether the organization had excess business holdings).

10b

Schedule A (Form 990 or 990-EZ) 2019

Page 5

Part IV

Supporting Organizations (continued)

Yes

Has the organization accepted a gift or contribution from any of the following persons?

A person who directly or indirectly controls, either alone or together with persons described in (b) and (c) below, the governing body of a supported organization?

11a

A family member of a person described in (a) above?

11b

A 35% controlled entity of a person described in (a) or (b) above? If “Yes” to a, b, or c, provide detail in Part VI.

11c

Section B. Type I Supporting Organizations

Yes

Did the directors, trustees, or membership of one or more supported organizations have the power to regularly appoint or elect at least a majority of the organization’s directors or trustees at all times during the tax year? If “No,” describe in Part VI how the supported organization(s) effectively operated, supervised, or controlled the organization’s activities. If the organization had more than one supported organization, describe how the powers to appoint and/or remove directors or trustees were allocated among the supported organizations and what conditions or restrictions, if any, applied to such powers during the tax year.

Did the organization operate for the benefit of any supported organization other than the supported organization(s) that operated, supervised, or controlled the supporting organization? If “Yes,” explain in Part VI how providing such benefit carried out the purposes of the supported organization(s) that operated, supervised or controlled the supporting organization.

Section C. Type II Supporting Organizations

Yes

Were a majority of the organization’s directors or trustees during the tax year also a majority of the directors or trustees of each of the organization’s supported organization(s)? If “No,” describe in Part VI how control or management of the supporting organization was vested in the same persons that controlled or managed the supported organization(s).

Section D. All Type III Supporting Organizations

Yes

Did the organization provide to each of its supported organizations, by the last day of the fifth month of the organization’s tax year, (i) a written notice describing the type and amount of support provided during the prior tax year, (ii) a copy of the Form 990 that was most recently filed as of the date of notification, and (iii) copies of the organization’s governing documents in effect on the date of notification, to the extent not previously provided?

Were any of the organization’s officers, directors, or trustees either (i) appointed or elected by the supported organization(s) or (ii) serving on the governing body of a supported organization? If "No," explain in Part VI how the organization maintained a close and continuous working relationship with the supported organization(s).

By reason of the relationship described in (2), did the organization’s supported organizations have a significant voice in the organization’s investment policies and in directing the use of the organization’s income or assets at all times during the tax year? If "Yes," describe in Part VI the role the organization’s supported organizations played in this regard.

Section E. Type III Functionally-Integrated Supporting Organizations

Check the box next to the method that the organization used to satisfy the Integral Part Test during the year (see instructions):

The organization satisfied the Activities Test. Complete line 2 below.

The organization is the parent of each of its supported organizations. Complete line 3 below.

The organization supported a governmental entity. Describe in Part VI how you supported a government entity (see instructions)

Activities Test. Answer (a) and (b) below.

Yes

Did substantially all of the organization’s activities during the tax year directly further the exempt purposes of the supported organization(s) to which the organization was responsive? If "Yes," then in Part VI identify those supported organizations and explain how these activities directly furthered their exempt purposes, how the organization was responsive to those supported organizations, and how the organization determined that these activities constituted substantially all of its activities.

Did the activities described in (a) constitute activities that, but for the organization’s involvement, one or more of the organization’s supported organization(s) would have been engaged in? If "Yes," explain in Part VI the reasons for the organization’s position that its supported organization(s) would have engaged in these activities but for the organization’s involvement.

Parent of Supported Organizations. Answer (a) and (b) below.

Did the organization have the power to regularly appoint or elect a majority of the officers, directors, or trustees of each of the supported organizations? Provide details in Part VI.

Did the organization exercise a substantial degree of direction over the policies, programs and activities of each of its supported organizations? If "Yes," describe in Part VI. the role played by the organization in this regard.

Schedule A (Form 990 or 990-EZ) 2019

Page 6

Part V

Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations

Check here if the organization satisfied the Integral Part Test as a qualifying trust on Nov. 20, 1970 (explain in Part VI). See instructions. All other Type III non-functionally integrated supporting organizations must complete Sections A through E.

	Section A - Adjusted Net Income		(A) Prior Year	(B) Current Year (optional)
1	Net short-term capital gain	1
2	Recoveries of prior-year distributions	2
3	Other gross income (see instructions)	3
4	Add lines 1 through 3	4
5	Depreciation and depletion	5
6	Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions)	6
7	Other expenses (see instructions)	7
8	Adjusted Net Income (subtract lines 5, 6 and 7 from line 4)	8

	Section B - Minimum Asset Amount		(A) Prior Year	(B) Current Year (optional)
1	Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year):	1
a	Average monthly value of securities	1a
b	Average monthly cash balances	1b
c	Fair market value of other non-exempt-use assets	1c
d	Total (add lines 1a, 1b, and 1c)	1d
e	Discount claimed for blockage or other factors (explain in detail in Part VI):
2	Acquisition indebtedness applicable to non-exempt use assets	2
3	Subtract line 2 from line 1d	3
4	Cash deemed held for exempt use. Enter 1-1/2% of line 3 (for greater amount, see instructions).	4
5	Net value of non-exempt-use assets (subtract line 4 from line 3)	5
6	Multiply line 5 by .035	6
7	Recoveries of prior-year distributions	7
8	Minimum Asset Amount (add line 7 to line 6)	8

	Section C - Distributable Amount		Current Year
1	Adjusted net income for prior year (from Section A, line 8, Column A)	1
2	Enter 85% of line 1	2
3	Minimum asset amount for prior year (from Section B, line 8, Column A)	3
4	Enter greater of line 2 or line 3	4
5	Income tax imposed in prior year	5
6	Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions)	6

Check here if the current year is the organization's first as a non-functionally-integrated Type III supporting organization (see instructions)

Schedule A (Form 990 or 990-EZ) 2019

Page 7

Part V

Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations(continued)

Section D - Distributions		Current Year
1 Amounts paid to supported organizations to accomplish exempt purposes
2 Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity
3 Administrative expenses paid to accomplish exempt purposes of supported organizations
4 Amounts paid to acquire exempt-use assets
5 Qualified set-aside amounts (prior IRS approval required)
6 Other distributions (describe in Part VI). See instructions
7Total annual distributions. Add lines 1 through 6.
8 Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions
9 Distributable amount for 2019 from Section C, line 6
10 Line 8 amount divided by Line 9 amount

Section E - Distribution Allocations (see instructions)		(i) Excess Distributions	(ii) Underdistributions Pre-2019	(iii) Distributable Amount for 2019
1 Distributable amount for 2019 from Section C, line 6
2 Underdistributions, if any, for years prior to 2019 (reasonable cause required-- explain in Part VI). See instructions.
3 Excess distributions carryover, if any, to 2019:
a From 2014.......
b From 2015.......
c From 2016.......
d From 2017.......
e From 2018.......
fTotal of lines 3a through e
g Applied to underdistributions of prior years
h Applied to 2019 distributable amount
i Carryover from 2014 not applied (see instructions)
j Remainder. Subtract lines 3g, 3h, and 3i from 3f.
4Distributions for 2019 from Section D, line 7:
$
a Applied to underdistributions of prior years
b Applied to 2019 distributable amount
c Remainder. Subtract lines 4a and 4b from 4.
5 Remaining underdistributions for years prior to 2019, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions.
6 Remaining underdistributions for 2019. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions.
7 Excess distributions carryover to 2020. Add lines 3j and 4c.
8 Breakdown of line 7:
a Excess from 2015.....
b Excess from 2016.....
c Excess from 2017.....
d Excess from 2018.....
e Excess from 2019.....

Schedule A (Form 990 or 990-EZ) (2019)

Schedule A (Form 990 or 990-EZ) 2019

Page 8

Part VI

Supplemental Information. Provide the explanations required by Part II, line 10; Part II, line 17a or 17b; Part III, line 12; Part IV, Section A, lines 1, 2, 3b, 3c, 4b, 4c, 5a, 6, 9a, 9b, 9c, 11a, 11b, and 11c; Part IV, Section B, lines 1 and 2; Part IV, Section C, line 1; Part IV, Section D, lines 2 and 3; Part IV, Section E, lines 1c, 2a, 2b, 3a and 3b; Part V, line 1; Part V, Section B, line 1e; Part V Section D, lines 5, 6, and 8; and Part V, Section E, lines 2, 5, and 6. Also complete this part for any additional information. (See instructions).

Facts And Circumstances Test

Return Reference	Explanation
PART I, LINE 4	IN 2019, STOWERS INSTITUTE FOR MEDICAL RESEARCH ("SIMR") SCIENTISTS COLLABORATED WITH RESEARCHERS AT 70 NATIONAL AND 50 INTERNATIONAL INSTITUTIONS INCLUDING DOZENS OF HOSPITALS, MEDICAL CENTERS, AND MEDICAL SCHOOLS. MANY OF THESE COLLABORATIONS RESULTED IN DISCOVERIES THAT MERITED PUBLICATION IN LEADING PEER-REVIEWED SCIENTIFIC JOURNALS AND/OR SUCCESSFULLY FUNDED GRANT AWARDS. SIMR CONDUCTS MEDICAL RESEARCH IN CONJUNCTION WITH THE UNIVERSITY OF KANSAS (KU) AND ITS AFFILIATES THE UNIVERSITY OF KANSAS HOSPITAL AUTHORITY AND THE UNIVERSITY OF KANSAS MEDICAL CENTER (KUMC), PURSUANT TO A WRITTEN MEMORANDUM OF UNDERSTANDING. KUMC IS THE ACADEMIC HEALTH SCIENCE CENTER OF THE LARGEST PUBLIC RESEARCH UNIVERSITY IN THE STATE OF KANSAS. KUMC OFFERS PROGRAMS AND SERVICES THAT FOCUS ON EDUCATION, RESEARCH, PATIENT CARE, AND COMMUNITY ENGAGEMENT. AS OF DECEMBER 31, 2019, FIVE KUMC STUDENTS HAVE RECEIVED MS DEGREES AND 45 KUMC STUDENTS HAVE RECEIVED PHD DEGREES FOR THESIS WORK PERFORMED IN SIMR'S LABS. KUMC IS AFFILIATED WITH THE UNIVERSITY OF KANSAS HOSPITAL, A NONPROFIT INDEPENDENT HOSPITAL CO-LOCATED WITH THE MAIN KUMC CAMPUS IN KANSAS CITY, KS. IN 2019, TWENTY SIMR RESEARCH PROGRAM LEADERS WERE ADJUNCT FACULTY IN FOUR KUMC DEPARTMENTS. THESE APPOINTMENTS INCLUDED 12 FULL PROFESSORS, FOUR ASSOCIATE PROFESSORS, AND FOUR ASSISTANT PROFESSORS. IN 2019, 52 OF SIMR'S 74 ORIGINAL RESEARCH PUBLICATIONS INCLUDED BOTH SIMR AND KUMC AFFILIATIONS. ABOUT A DOZEN KUMC STUDENTS PERFORMED PREDOCTORAL RESEARCH IN SIMR LABS IN 2019. SIMR IS ALSO A CONSORTIUM MEMBER OF THE UNIVERSITY OF KANSAS CANCER CENTER AT KUMC, A CANCER RESEARCH AND CARE PARTNERSHIP SPANNING TWO STATES AND INVOLVING COLLABORATION AMONG RESEARCHERS, PHYSICIANS, AND CANCER SUPPORT PROFESSIONALS IN BASIC, TRANSLATIONAL, AND CLINICAL RESEARCH AREAS. IN JUNE 2012, THE NIH'S NATIONAL CANCER INSTITUTE (NCI) NAMED THE UNIVERSITY OF KANSAS CANCER CENTER A NCI-DESIGNATED CANCER CENTER. THE NCI CANCER CENTERS PROGRAM IS A PILLAR OF FEDERAL CANCER RESEARCH EFFORTS AND INTEGRAL TO THE NCI'S PROGRAMS FOR STUDYING, TREATING, AND PREVENTING CANCER. IN KUMC'S APPLICATION TO THE NCI CANCER CENTERS PROGRAM, $4 MILLION OF THE $48 MILLION IN GRANTS CITED IN THE APPLICATION WERE GRANTS THAT HAD BEEN AWARDED TO SIMR INVESTIGATORS. IN 2019, 12 SIMR RESEARCH PROGRAM LEADERS WERE MEMBERS OF THE UNIVERSITY OF KANSAS CANCER CENTER'S CANCER BIOLOGY RESEARCH PROGRAM, INCLUDING LINHENG LI, PHD, WHO SERVES AS CO-LEADER OF THE PROGRAM. IN 2019, SIMR RESEARCH PROGRAM LEADER MICHAEL WASHBURN, PHD, CONTINUED A RESEARCH PROJECT IN COLLABORATION WITH ROY JENSEN, MD, DIRECTOR OF THE UNIVERSITY OF KANSAS CANCER CENTER. THE OVERALL AIM OF THIS RESEARCH EFFORT IS TO DETERMINE HOW CANCER THERAPEUTICS ACT ON PROTEIN NETWORKS IN CELLS AND TISSUES. DR. JENSEN IS A WORLD-RENOWNED EXPERT ON BREAST CANCER AND HOLDS ADDITIONAL POSITIONS AS DIRECTOR, KANSAS MASONIC CANCER RESEARCH INSTITUTE, WILLIAM R. JEWELL DISTINGUISHED KANSAS MASONIC PROFESSOR, AND PROFESSOR OF PATHOLOGY AND LABORATORY MEDICINE, ANATOMY AND CELL BIOLOGY, CANCER BIOLOGY, AND MOLECULAR BIOSCIENCES AT KUMC. THE PROJECT AIMS TO FURTHER EXPLORE THE MECHANISM OF ACTION OF SUBEROYLANILIDE HYDROXAMIC ACID (SAHA), WHICH IS USED AS CHEMOTHERAPY FOR CERTAIN LYMPHOMAS AND IS BEING EVALUATED IN CLINICAL TRIALS FOR OTHER CANCERS. RECENT REPORTS SUGGEST THAT SAHA HAS ADDITIONAL EFFECTS THAT INVOLVE PROTEIN NETWORKS MORE BROADLY, THUS SUGGESTING OTHER POSSIBLE MECHANISMS OF ACTION. RESULTS FROM THIS JOINT RESEARCH EFFORT MAY ENABLE THE FUTURE DEVELOPMENT OF MORE SPECIFIC AND EFFECTIVE HUMAN THERAPEUTICS. THIS PROJECT IS SUPPORTED IN PART BY A NIH GRANT FROM THE NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES. IN 2019, SIMR RESEARCH PROGRAM LEADER LINHENG LI, PHD, CONTINUED A COLLABORATION WITH THE UNIVERSITY OF KANSAS CANCER CENTER AND CHILDREN'S MERCY HOSPITAL, KANSAS CITY, MO, TO INVESTIGATE APPROACHES TO TREAT LEUKEMIA. THIS RESEARCH FOCUSES ON TARGETING CANCER STEM CELLS TO HELP REDUCE THE RECURRENCE OF CANCER AFTER A PATIENT GOES INTO REMISSION. THE COLLABORATION BUILDS ON FOUNDATIONAL RESEARCH FROM THE LI LAB THAT HAS CHARACTERIZED CANCER STEM CELLS AT MOLECULAR AND CELLULAR LEVELS. THIS ONGOING RESEARCH COLLABORATION HAS GENERATED FINDINGS THAT HAVE BEEN REPORTED IN ORIGINAL RESEARCH PUBLICATIONS INCLUDING ZHAO M ET AL, 2019. KUMC IS THE SPONSOR OF A RELATED CLINICAL RESEARCH STUDY, "LOW-DOSE DAUNORUBICIN IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIA," WHICH IS DESIGNED TO ASSESS THE FEASIBILITY AND TOLERABILITY OF ADMINISTERING A LOW DOSE OF THE DRUG TO PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) OR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), AND TO OBTAIN PRELIMINARY DATA ON THE DRUG ENGAGING ITS TARGET. SIMR PARTICIPATED IN COLLABORATIONS CONDUCTING RESEARCH IN CONJUNCTION WITH THE FOLLOWING US HOSPITALS, PURSUANT TO AN UNDERSTANDING TO MAINTAIN CONTINUING CLOSE COOPERATION IN THE ACTIVE CONDUCT OF MEDICAL RESEARCH IN 2019: INSTITUTION LOCATION BRIGHAM AND WOMEN'S HOSPITAL BOSTON, MA CHILDREN'S HOSPITAL OF PHILADELPHIA PHILADELPHIA, PA CHILDREN'S MERCY HOSPITAL KANSAS CITY, MO CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER CINCINNATI, OH DANA-FARBER CANCER INSTITUTE BOSTON, MA FRED HUTCHINSON CANCER RESEARCH CENTER SEATTLE, WA GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES WASHINGTON, DC GREATER BALTIMORE MEDICAL CENTER TOWSON, MD HARVARD MEDICAL SCHOOL BOSTON, MA JOHNS HOPKINS SCHOOL OF MEDICINE BALTIMORE, MD NEW YORK UNIVERSITY SCHOOL OF MEDICINE NEW YORK, NY NORTHWESTERN UNIVERSITY FEINBERG SCHOOL OF MEDICINE CHICAGO, IL OREGON HEALTH AND SCIENCE UNIVERSITY SCHOOL OF MEDICINE PORTLAND, OR PERLMUTTER CANCER CENTER NEW YORK, NY SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE ST LOUIS, MO SEATTLE CHILDREN'S HOSPITAL SEATTLE, WA SINAI HOSPITAL OF BALTIMORE BALTIMORE, MD STANFORD UNIVERSITY SCHOOL OF MEDICINE PALO ALTO, CA UNIVERSITY OF CALIFORNIA LOS ANGELES DAVID GEFFEN SCHOOL OF MEDICINE LOS ANGELES, CA UNIVERSITY OF CALIFORNIA SAN FRANCISCO SAN FRANCISCO, CA UNIVERSITY OF KANSAS CANCER CENTER KANSAS CITY, KS UNIVERSITY OF KANSAS MEDICAL CENTER KANSAS CITY, KS UNIVERSITY OF PENNSYLVANIA PERELMAN SCHOOL OF MEDICINE PHILADELPHIA, PA UNIVERSITY OF PITTSBURGH CANCER INSTITUTE PITTSBURGH, PA UNIVERSITY OF ROCHESTER MEDICAL CENTER ROCHESTER, NY UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE COLUMBIA, SC UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER MEMPHIS, TN UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER HOUSTON, TX WEILL CORNELL MEDICINE NEW YORK, NY TO CARRY OUT THE RESEARCH DESCRIBED IN THE FOLLOWING EXAMPLES, SIMR AND HOSPITAL, MEDICAL CENTER, OR MEDICAL SCHOOL ENTERED INTO A COOPERATION AGREEMENT PURSUANT TO WHICH THEY AGREED TO ESTABLISH, DEVELOP, ADMINISTER, AND MAINTAIN CONTINUING CLOSE COOPERATION IN THE ACTIVE CONDUCT OF MEDICAL RESEARCH, INCLUDING THROUGH SPECIFIC COOPERATIVE EFFORTS IN THE AREAS OF RESEARCH, SHARING OF INFORMATION, PURSUANT OF JOINT GRANTS, INTERACTION OF STAFF, ADJUNCT/JOINT APPOINTMENTS, AND SHARING OF FACILITIES. IN ORDER TO ASSURE THE SUCCESS OF THEIR COOPERATIVE RELATIONSHIP, EACH AGREED TO ENGAGE IN EFFECTIVE, COORDINATED AND ONGOING PLANNING, OVERSIGHT, AND COMMUNICATION, AND TO COMMIT THE NECESSARY RESOURCES, BOTH HUMAN AND MONETARY, TO SUPPORT, FACILITATE, AND PROMOTE THE COOPERATION.
JOINT MEDICAL RESEARCH ON THE CHARACTERIZATION OF INTESTINAL STEM CELLS -	THE LI LAB PERFORMED JOINT MEDICAL RESEARCH ON THE CHARACTERIZATION OF INTESTINAL STEM CELLS WITH COLLABORATORS AT CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER, DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA, OREGON HEALTH AND SCIENCE UNIVERSITY SCHOOL OF MEDICINE, STANFORD UNIVERSITY SCHOOL OF MEDICINE, AND UNIVERSITY OF PITTSBURGH CANCER INSTITUTE. INTESTINAL DISEASES RANGING FROM CROHN'S DISEASE TO COLITIS TO CANCER MAY BENEFIT FROM INTESTINAL STEM CELL THERAPIES. THIS RESEARCH ADVANCES THE UNDERSTANDING OF THE BIOLOGY OF STEM CELLS THAT RESIDE IN THE INTESTINE AND EXPLORES HOW THEY CAN BE USED TO TREAT AND CURE INTESTINAL DISEASES. THIS ONGOING RESEARCH COLLABORATION IS SUPPORTED IN PART BY A NIH GRANT AWARDED BY THE NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES. JOINT MEDICAL RESEARCH ON EYE DEVELOPMENT AND FUNCTION - THE XIE LAB PERFORMED JOINT MEDICAL RESEARCH ON GENETIC PROGRAMS THAT REGULATE THE MAMMALIAN EYE WITH COLLABORATORS AT CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER, UNIVERSITY OF ROCHESTER MEDICAL CENTER, AND KYOTO UNIVERSITY. AN EYE STRUCTURE CALLED THE CILIARY BODY IS IMPORTANT FOR CHANGING THE SHAPE OF THE LENS AND FOR PRODUCTION OF THE AQUEOUS HUMOR, THE FLUID THAT MAINTAINS PRESSURE IN THE EYE. DEFECTS IN LENS ACCOMMODATION LEAD TO MYOPIA OR NEARSIGHTEDNESS, WHILE HIGH PRESSURE WITHIN THE EYE IS ONE OF THE MOST IMPORTANT RISK FACTORS FOR GLAUCOMA, THE SECOND LEADING BLIND-CAUSING DISEASE. THE GOAL OF THIS RESEARCH IS TO REVEAL THE MECHANISMS REGULATING THE DEVELOPMENT AND SECRETION OF THE CILIARY BODY. KNOWLEDGE GAINED FROM THESE STUDIES MAY ENHANCE TREATMENTS FOR GLAUCOMA AND MYOPIA. THIS RESEARCH IS SUPPORTED IN PART BY A NIH GRANT FROM THE NATIONAL EYE INSTITUTE. OTHER US COLLABORATORS INCLUDED BERNICE PAUAHI BISHOP MUSEUM, BOSTON COLLEGE, CALIFORNIA INSTITUTE OF TECHNOLOGY, COLD SPRING HARBOR LABORATORY, CORNELIA DE LANGE SYNDROME FOUNDATION, ELMHURST COLLEGE, FLORIDA ATLANTIC UNIVERSITY, HOWARD HUGHES MEDICAL INSTITUTE, INDIANA UNIVERSITY, JOHNS HOPKINS UNIVERSITY, LAWRENCE BERKELEY LABORATORY, MARQUETTE UNIVERSITY, MILLERSVILLE UNIVERSITY, MORGRIDGE INSTITUTE FOR RESEARCH, NATIONAL CANCER INSTITUTE OF THE NATIONAL INSTITUTES OF HEALTH, NATURAL HISTORY MUSEUM OF LOS ANGELES COUNTY, NEW YORK STATE DEPARTMENT OF HEALTH, NEW YORK UNIVERSITY, OPEN UNIVERSITY, PRINCETON UNIVERSITY, PURDUE UNIVERSITY, RUTGERS UNIVERSITY, SOUTHEASTERN LOUISIANA UNIVERSITY, UNIVERSITY OF CALIFORNIA DAVIS, UNIVERSITY OF CALIFORNIA IRVINE, UNIVERSITY OF CALIFORNIA MERCED, UNIVERSITY OF CALIFORNIA SAN DIEGO, UNIVERSITY OF FLORIDA ST AUGUSTINE, UNIVERSITY OF FLORIDA GAINESVILLE, UNIVERSITY OF KANSAS, UNIVERSITY OF KENTUCKY, UNIVERSITY OF MARYLAND, UNIVERSITY OF MINNESOTA, UNIVERSITY OF MISSOURI-KANSAS CITY, UNIVERSITY OF PITTSBURGH, UNIVERSITY OF TEXAS AT ARLINGTON, UNIVERSITY OF VIRGINIA, UNIVERSITY OF WASHINGTON, UNIVERSITY OF WISCONSIN-MADISON, VIRGINIA COMMONWEALTH UNIVERSITY, AND WASHINGTON UNIVERSITY IN ST LOUIS. SIMR COLLABORATED WITH THE FOLLOWING INTERNATIONAL HOSPITALS, MEDICAL CENTERS, AND MEDICAL SCHOOLS IN 2019: BEIJING PERFECT FAMILY HOSPITAL, CHINA; CHINESE ACADEMY OF MEDICAL SCIENCES, TIANJIN, CHINA; HENAN PROVINCIAL PEOPLE'S HOSPITAL, ZHENGZHOU, CHINA; HONG KONG BAPTIST UNIVERSITY, CHINA; HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY, CHINA; PEKING UNION MEDICAL COLLEGE, TIANJIN, CHINA; THIRD AFFILIATED HOSPITAL OF SUN YAT-SEN UNIVERSITY, GUANGZHOU, CHINA; TIANJIN MEDICAL UNIVERSITY, HEPING, CHINA; TSINGHUA UNIVERSITY SCHOOL OF MEDICINE,BEIJING, CHINA; WUHAN NO.1 HOSPITAL, HUBEI, CHINA; AND ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE, HANGZHOU, CHINA. OTHER INTERNATIONAL COLLABORATORS INCLUDED AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, SINGAPORE; BARCELONA INSTITUTE OF SCIENCE AND TECHNOLOGY, SPAIN; CARDIFF UNIVERSITY, CATHAYS, UNITED KINGDOM; CENTRO DE INVESTIGACION BIOMEDICA EN RED EN BIOINGENIERIA, MADRID, SPAIN; CIENCIAS BIOLOGICAS, QUITO, ECUADOR; CZECH ACADEMY OF SCIENCES, PRAGUE; DURHAM UNIVERSITY, UNITED KINGDOM; ECOLE POLYTECHNIQUE, PALAISEAU, FRANCE; FRIEDRICH MIESCHER LABORATORY OF THE MAX PLANCK SOCIETY, TUBINGEN, GERMANY; HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY, WUHAN, HUBEI, CHINA; HUBEI UNIVERSITY, WUHAN, CHINA; INSTITUTO DE FISIOLOGIA, MENDOZA, ARGENTINA; INSTITUTO DE HISTOLOGIA Y EMBRIOLOGIA, MENDOZA, ARGENTINA; INTERNATIONAL IBERIAN NANOTECHNOLOGY LABORATORY, BRAGA, PORTUGAL; ISRAEL INSTITUTE OF TECHNOLOGY, HAIFA; JILIN UNIVERSITY, CHANGCHUN, CHINA; KIEL UNIVERSITY, GERMANY; KYOTO UNIVERSITY, JAPAN; MAX PLANCK INSTITUTE FOR EVOLUTIONARY BIOLOGY, PLON, GERMANY; MAX PLANCK INSTITUTE OF MOLECULAR CELL BIOLOGY AND GENETICS, DRESDEN, GERMANY; NATIONAL RESEARCH COUNCIL, PISA, ITALY; OSAKA UNIVERSITY, JAPAN; RESEARCH CENTRE FOR MEDICAL GENETICS, MOSCOW, RUSSIA; SEJONG UNIVERSITY, SEOUL, KOREA; SHENZHEN UNIVERSITY, CHINA; SUN YAT-SEN UNIVERSITY, GUANGZHOU, CHINA; TEL AVIV UNIVERSITY, ISRAEL; TOHOKU UNIVERSITY, SENDAI, JAPAN; TSINGHUA UNIVERSITY, BEIJING, CHINA; UNIVERSITY OF HELSINKI, FINLAND; UNIVERSITY OF MILAN, ITALY; UNIVERSITY OF SASKATCHEWAN, SASKATOON, CANADA; UNIVERSITY OF SCIENCE AND TECHNOLOGY, HONG KONG, CHINA; UNIVERSITY OF TOKYO, JAPAN; UNIVERSITY OF TORONTO, CANADA; UNIVERSITY OF WURZBURG, GERMANY; UNIVERSITY OF ZURICH, SWITZERLAND; WELLCOME SANGER INSTITUTE, HINXTON, UNITED KINGDOM; AND YONSEI UNIVERSITY COLLEGE OF DENTISTRY, SEOUL, KOREA.

Return Reference

Explanation

PART I, LINE 4

IN 2019, STOWERS INSTITUTE FOR MEDICAL RESEARCH ("SIMR") SCIENTISTS COLLABORATED WITH RESEARCHERS AT 70 NATIONAL AND 50 INTERNATIONAL INSTITUTIONS INCLUDING DOZENS OF HOSPITALS, MEDICAL CENTERS, AND MEDICAL SCHOOLS. MANY OF THESE COLLABORATIONS RESULTED IN DISCOVERIES THAT MERITED PUBLICATION IN LEADING PEER-REVIEWED SCIENTIFIC JOURNALS AND/OR SUCCESSFULLY FUNDED GRANT AWARDS. SIMR CONDUCTS MEDICAL RESEARCH IN CONJUNCTION WITH THE UNIVERSITY OF KANSAS (KU) AND ITS AFFILIATES THE UNIVERSITY OF KANSAS HOSPITAL AUTHORITY AND THE UNIVERSITY OF KANSAS MEDICAL CENTER (KUMC), PURSUANT TO A WRITTEN MEMORANDUM OF UNDERSTANDING. KUMC IS THE ACADEMIC HEALTH SCIENCE CENTER OF THE LARGEST PUBLIC RESEARCH UNIVERSITY IN THE STATE OF KANSAS. KUMC OFFERS PROGRAMS AND SERVICES THAT FOCUS ON EDUCATION, RESEARCH, PATIENT CARE, AND COMMUNITY ENGAGEMENT. AS OF DECEMBER 31, 2019, FIVE KUMC STUDENTS HAVE RECEIVED MS DEGREES AND 45 KUMC STUDENTS HAVE RECEIVED PHD DEGREES FOR THESIS WORK PERFORMED IN SIMR'S LABS. KUMC IS AFFILIATED WITH THE UNIVERSITY OF KANSAS HOSPITAL, A NONPROFIT INDEPENDENT HOSPITAL CO-LOCATED WITH THE MAIN KUMC CAMPUS IN KANSAS CITY, KS. IN 2019, TWENTY SIMR RESEARCH PROGRAM LEADERS WERE ADJUNCT FACULTY IN FOUR KUMC DEPARTMENTS. THESE APPOINTMENTS INCLUDED 12 FULL PROFESSORS, FOUR ASSOCIATE PROFESSORS, AND FOUR ASSISTANT PROFESSORS. IN 2019, 52 OF SIMR'S 74 ORIGINAL RESEARCH PUBLICATIONS INCLUDED BOTH SIMR AND KUMC AFFILIATIONS. ABOUT A DOZEN KUMC STUDENTS PERFORMED PREDOCTORAL RESEARCH IN SIMR LABS IN 2019. SIMR IS ALSO A CONSORTIUM MEMBER OF THE UNIVERSITY OF KANSAS CANCER CENTER AT KUMC, A CANCER RESEARCH AND CARE PARTNERSHIP SPANNING TWO STATES AND INVOLVING COLLABORATION AMONG RESEARCHERS, PHYSICIANS, AND CANCER SUPPORT PROFESSIONALS IN BASIC, TRANSLATIONAL, AND CLINICAL RESEARCH AREAS. IN JUNE 2012, THE NIH'S NATIONAL CANCER INSTITUTE (NCI) NAMED THE UNIVERSITY OF KANSAS CANCER CENTER A NCI-DESIGNATED CANCER CENTER. THE NCI CANCER CENTERS PROGRAM IS A PILLAR OF FEDERAL CANCER RESEARCH EFFORTS AND INTEGRAL TO THE NCI'S PROGRAMS FOR STUDYING, TREATING, AND PREVENTING CANCER. IN KUMC'S APPLICATION TO THE NCI CANCER CENTERS PROGRAM, $4 MILLION OF THE $48 MILLION IN GRANTS CITED IN THE APPLICATION WERE GRANTS THAT HAD BEEN AWARDED TO SIMR INVESTIGATORS. IN 2019, 12 SIMR RESEARCH PROGRAM LEADERS WERE MEMBERS OF THE UNIVERSITY OF KANSAS CANCER CENTER'S CANCER BIOLOGY RESEARCH PROGRAM, INCLUDING LINHENG LI, PHD, WHO SERVES AS CO-LEADER OF THE PROGRAM. IN 2019, SIMR RESEARCH PROGRAM LEADER MICHAEL WASHBURN, PHD, CONTINUED A RESEARCH PROJECT IN COLLABORATION WITH ROY JENSEN, MD, DIRECTOR OF THE UNIVERSITY OF KANSAS CANCER CENTER. THE OVERALL AIM OF THIS RESEARCH EFFORT IS TO DETERMINE HOW CANCER THERAPEUTICS ACT ON PROTEIN NETWORKS IN CELLS AND TISSUES. DR. JENSEN IS A WORLD-RENOWNED EXPERT ON BREAST CANCER AND HOLDS ADDITIONAL POSITIONS AS DIRECTOR, KANSAS MASONIC CANCER RESEARCH INSTITUTE, WILLIAM R. JEWELL DISTINGUISHED KANSAS MASONIC PROFESSOR, AND PROFESSOR OF PATHOLOGY AND LABORATORY MEDICINE, ANATOMY AND CELL BIOLOGY, CANCER BIOLOGY, AND MOLECULAR BIOSCIENCES AT KUMC. THE PROJECT AIMS TO FURTHER EXPLORE THE MECHANISM OF ACTION OF SUBEROYLANILIDE HYDROXAMIC ACID (SAHA), WHICH IS USED AS CHEMOTHERAPY FOR CERTAIN LYMPHOMAS AND IS BEING EVALUATED IN CLINICAL TRIALS FOR OTHER CANCERS. RECENT REPORTS SUGGEST THAT SAHA HAS ADDITIONAL EFFECTS THAT INVOLVE PROTEIN NETWORKS MORE BROADLY, THUS SUGGESTING OTHER POSSIBLE MECHANISMS OF ACTION. RESULTS FROM THIS JOINT RESEARCH EFFORT MAY ENABLE THE FUTURE DEVELOPMENT OF MORE SPECIFIC AND EFFECTIVE HUMAN THERAPEUTICS. THIS PROJECT IS SUPPORTED IN PART BY A NIH GRANT FROM THE NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES. IN 2019, SIMR RESEARCH PROGRAM LEADER LINHENG LI, PHD, CONTINUED A COLLABORATION WITH THE UNIVERSITY OF KANSAS CANCER CENTER AND CHILDREN'S MERCY HOSPITAL, KANSAS CITY, MO, TO INVESTIGATE APPROACHES TO TREAT LEUKEMIA. THIS RESEARCH FOCUSES ON TARGETING CANCER STEM CELLS TO HELP REDUCE THE RECURRENCE OF CANCER AFTER A PATIENT GOES INTO REMISSION. THE COLLABORATION BUILDS ON FOUNDATIONAL RESEARCH FROM THE LI LAB THAT HAS CHARACTERIZED CANCER STEM CELLS AT MOLECULAR AND CELLULAR LEVELS. THIS ONGOING RESEARCH COLLABORATION HAS GENERATED FINDINGS THAT HAVE BEEN REPORTED IN ORIGINAL RESEARCH PUBLICATIONS INCLUDING ZHAO M ET AL, 2019. KUMC IS THE SPONSOR OF A RELATED CLINICAL RESEARCH STUDY, "LOW-DOSE DAUNORUBICIN IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIA," WHICH IS DESIGNED TO ASSESS THE FEASIBILITY AND TOLERABILITY OF ADMINISTERING A LOW DOSE OF THE DRUG TO PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) OR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), AND TO OBTAIN PRELIMINARY DATA ON THE DRUG ENGAGING ITS TARGET. SIMR PARTICIPATED IN COLLABORATIONS CONDUCTING RESEARCH IN CONJUNCTION WITH THE FOLLOWING US HOSPITALS, PURSUANT TO AN UNDERSTANDING TO MAINTAIN CONTINUING CLOSE COOPERATION IN THE ACTIVE CONDUCT OF MEDICAL RESEARCH IN 2019: INSTITUTION LOCATION BRIGHAM AND WOMEN'S HOSPITAL BOSTON, MA CHILDREN'S HOSPITAL OF PHILADELPHIA PHILADELPHIA, PA CHILDREN'S MERCY HOSPITAL KANSAS CITY, MO CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER CINCINNATI, OH DANA-FARBER CANCER INSTITUTE BOSTON, MA FRED HUTCHINSON CANCER RESEARCH CENTER SEATTLE, WA GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES WASHINGTON, DC GREATER BALTIMORE MEDICAL CENTER TOWSON, MD HARVARD MEDICAL SCHOOL BOSTON, MA JOHNS HOPKINS SCHOOL OF MEDICINE BALTIMORE, MD NEW YORK UNIVERSITY SCHOOL OF MEDICINE NEW YORK, NY NORTHWESTERN UNIVERSITY FEINBERG SCHOOL OF MEDICINE CHICAGO, IL OREGON HEALTH AND SCIENCE UNIVERSITY SCHOOL OF MEDICINE PORTLAND, OR PERLMUTTER CANCER CENTER NEW YORK, NY SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE ST LOUIS, MO SEATTLE CHILDREN'S HOSPITAL SEATTLE, WA SINAI HOSPITAL OF BALTIMORE BALTIMORE, MD STANFORD UNIVERSITY SCHOOL OF MEDICINE PALO ALTO, CA UNIVERSITY OF CALIFORNIA LOS ANGELES DAVID GEFFEN SCHOOL OF MEDICINE LOS ANGELES, CA UNIVERSITY OF CALIFORNIA SAN FRANCISCO SAN FRANCISCO, CA UNIVERSITY OF KANSAS CANCER CENTER KANSAS CITY, KS UNIVERSITY OF KANSAS MEDICAL CENTER KANSAS CITY, KS UNIVERSITY OF PENNSYLVANIA PERELMAN SCHOOL OF MEDICINE PHILADELPHIA, PA UNIVERSITY OF PITTSBURGH CANCER INSTITUTE PITTSBURGH, PA UNIVERSITY OF ROCHESTER MEDICAL CENTER ROCHESTER, NY UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE COLUMBIA, SC UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER MEMPHIS, TN UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER HOUSTON, TX WEILL CORNELL MEDICINE NEW YORK, NY TO CARRY OUT THE RESEARCH DESCRIBED IN THE FOLLOWING EXAMPLES, SIMR AND HOSPITAL, MEDICAL CENTER, OR MEDICAL SCHOOL ENTERED INTO A COOPERATION AGREEMENT PURSUANT TO WHICH THEY AGREED TO ESTABLISH, DEVELOP, ADMINISTER, AND MAINTAIN CONTINUING CLOSE COOPERATION IN THE ACTIVE CONDUCT OF MEDICAL RESEARCH, INCLUDING THROUGH SPECIFIC COOPERATIVE EFFORTS IN THE AREAS OF RESEARCH, SHARING OF INFORMATION, PURSUANT OF JOINT GRANTS, INTERACTION OF STAFF, ADJUNCT/JOINT APPOINTMENTS, AND SHARING OF FACILITIES. IN ORDER TO ASSURE THE SUCCESS OF THEIR COOPERATIVE RELATIONSHIP, EACH AGREED TO ENGAGE IN EFFECTIVE, COORDINATED AND ONGOING PLANNING, OVERSIGHT, AND COMMUNICATION, AND TO COMMIT THE NECESSARY RESOURCES, BOTH HUMAN AND MONETARY, TO SUPPORT, FACILITATE, AND PROMOTE THE COOPERATION.

JOINT MEDICAL RESEARCH ON THE CHARACTERIZATION OF INTESTINAL STEM CELLS -

THE LI LAB PERFORMED JOINT MEDICAL RESEARCH ON THE CHARACTERIZATION OF INTESTINAL STEM CELLS WITH COLLABORATORS AT CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER, DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA, OREGON HEALTH AND SCIENCE UNIVERSITY SCHOOL OF MEDICINE, STANFORD UNIVERSITY SCHOOL OF MEDICINE, AND UNIVERSITY OF PITTSBURGH CANCER INSTITUTE. INTESTINAL DISEASES RANGING FROM CROHN'S DISEASE TO COLITIS TO CANCER MAY BENEFIT FROM INTESTINAL STEM CELL THERAPIES. THIS RESEARCH ADVANCES THE UNDERSTANDING OF THE BIOLOGY OF STEM CELLS THAT RESIDE IN THE INTESTINE AND EXPLORES HOW THEY CAN BE USED TO TREAT AND CURE INTESTINAL DISEASES. THIS ONGOING RESEARCH COLLABORATION IS SUPPORTED IN PART BY A NIH GRANT AWARDED BY THE NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES. JOINT MEDICAL RESEARCH ON EYE DEVELOPMENT AND FUNCTION - THE XIE LAB PERFORMED JOINT MEDICAL RESEARCH ON GENETIC PROGRAMS THAT REGULATE THE MAMMALIAN EYE WITH COLLABORATORS AT CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER, UNIVERSITY OF ROCHESTER MEDICAL CENTER, AND KYOTO UNIVERSITY. AN EYE STRUCTURE CALLED THE CILIARY BODY IS IMPORTANT FOR CHANGING THE SHAPE OF THE LENS AND FOR PRODUCTION OF THE AQUEOUS HUMOR, THE FLUID THAT MAINTAINS PRESSURE IN THE EYE. DEFECTS IN LENS ACCOMMODATION LEAD TO MYOPIA OR NEARSIGHTEDNESS, WHILE HIGH PRESSURE WITHIN THE EYE IS ONE OF THE MOST IMPORTANT RISK FACTORS FOR GLAUCOMA, THE SECOND LEADING BLIND-CAUSING DISEASE. THE GOAL OF THIS RESEARCH IS TO REVEAL THE MECHANISMS REGULATING THE DEVELOPMENT AND SECRETION OF THE CILIARY BODY. KNOWLEDGE GAINED FROM THESE STUDIES MAY ENHANCE TREATMENTS FOR GLAUCOMA AND MYOPIA. THIS RESEARCH IS SUPPORTED IN PART BY A NIH GRANT FROM THE NATIONAL EYE INSTITUTE. OTHER US COLLABORATORS INCLUDED BERNICE PAUAHI BISHOP MUSEUM, BOSTON COLLEGE, CALIFORNIA INSTITUTE OF TECHNOLOGY, COLD SPRING HARBOR LABORATORY, CORNELIA DE LANGE SYNDROME FOUNDATION, ELMHURST COLLEGE, FLORIDA ATLANTIC UNIVERSITY, HOWARD HUGHES MEDICAL INSTITUTE, INDIANA UNIVERSITY, JOHNS HOPKINS UNIVERSITY, LAWRENCE BERKELEY LABORATORY, MARQUETTE UNIVERSITY, MILLERSVILLE UNIVERSITY, MORGRIDGE INSTITUTE FOR RESEARCH, NATIONAL CANCER INSTITUTE OF THE NATIONAL INSTITUTES OF HEALTH, NATURAL HISTORY MUSEUM OF LOS ANGELES COUNTY, NEW YORK STATE DEPARTMENT OF HEALTH, NEW YORK UNIVERSITY, OPEN UNIVERSITY, PRINCETON UNIVERSITY, PURDUE UNIVERSITY, RUTGERS UNIVERSITY, SOUTHEASTERN LOUISIANA UNIVERSITY, UNIVERSITY OF CALIFORNIA DAVIS, UNIVERSITY OF CALIFORNIA IRVINE, UNIVERSITY OF CALIFORNIA MERCED, UNIVERSITY OF CALIFORNIA SAN DIEGO, UNIVERSITY OF FLORIDA ST AUGUSTINE, UNIVERSITY OF FLORIDA GAINESVILLE, UNIVERSITY OF KANSAS, UNIVERSITY OF KENTUCKY, UNIVERSITY OF MARYLAND, UNIVERSITY OF MINNESOTA, UNIVERSITY OF MISSOURI-KANSAS CITY, UNIVERSITY OF PITTSBURGH, UNIVERSITY OF TEXAS AT ARLINGTON, UNIVERSITY OF VIRGINIA, UNIVERSITY OF WASHINGTON, UNIVERSITY OF WISCONSIN-MADISON, VIRGINIA COMMONWEALTH UNIVERSITY, AND WASHINGTON UNIVERSITY IN ST LOUIS. SIMR COLLABORATED WITH THE FOLLOWING INTERNATIONAL HOSPITALS, MEDICAL CENTERS, AND MEDICAL SCHOOLS IN 2019: BEIJING PERFECT FAMILY HOSPITAL, CHINA; CHINESE ACADEMY OF MEDICAL SCIENCES, TIANJIN, CHINA; HENAN PROVINCIAL PEOPLE'S HOSPITAL, ZHENGZHOU, CHINA; HONG KONG BAPTIST UNIVERSITY, CHINA; HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY, CHINA; PEKING UNION MEDICAL COLLEGE, TIANJIN, CHINA; THIRD AFFILIATED HOSPITAL OF SUN YAT-SEN UNIVERSITY, GUANGZHOU, CHINA; TIANJIN MEDICAL UNIVERSITY, HEPING, CHINA; TSINGHUA UNIVERSITY SCHOOL OF MEDICINE,BEIJING, CHINA; WUHAN NO.1 HOSPITAL, HUBEI, CHINA; AND ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE, HANGZHOU, CHINA. OTHER INTERNATIONAL COLLABORATORS INCLUDED AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, SINGAPORE; BARCELONA INSTITUTE OF SCIENCE AND TECHNOLOGY, SPAIN; CARDIFF UNIVERSITY, CATHAYS, UNITED KINGDOM; CENTRO DE INVESTIGACION BIOMEDICA EN RED EN BIOINGENIERIA, MADRID, SPAIN; CIENCIAS BIOLOGICAS, QUITO, ECUADOR; CZECH ACADEMY OF SCIENCES, PRAGUE; DURHAM UNIVERSITY, UNITED KINGDOM; ECOLE POLYTECHNIQUE, PALAISEAU, FRANCE; FRIEDRICH MIESCHER LABORATORY OF THE MAX PLANCK SOCIETY, TUBINGEN, GERMANY; HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY, WUHAN, HUBEI, CHINA; HUBEI UNIVERSITY, WUHAN, CHINA; INSTITUTO DE FISIOLOGIA, MENDOZA, ARGENTINA; INSTITUTO DE HISTOLOGIA Y EMBRIOLOGIA, MENDOZA, ARGENTINA; INTERNATIONAL IBERIAN NANOTECHNOLOGY LABORATORY, BRAGA, PORTUGAL; ISRAEL INSTITUTE OF TECHNOLOGY, HAIFA; JILIN UNIVERSITY, CHANGCHUN, CHINA; KIEL UNIVERSITY, GERMANY; KYOTO UNIVERSITY, JAPAN; MAX PLANCK INSTITUTE FOR EVOLUTIONARY BIOLOGY, PLON, GERMANY; MAX PLANCK INSTITUTE OF MOLECULAR CELL BIOLOGY AND GENETICS, DRESDEN, GERMANY; NATIONAL RESEARCH COUNCIL, PISA, ITALY; OSAKA UNIVERSITY, JAPAN; RESEARCH CENTRE FOR MEDICAL GENETICS, MOSCOW, RUSSIA; SEJONG UNIVERSITY, SEOUL, KOREA; SHENZHEN UNIVERSITY, CHINA; SUN YAT-SEN UNIVERSITY, GUANGZHOU, CHINA; TEL AVIV UNIVERSITY, ISRAEL; TOHOKU UNIVERSITY, SENDAI, JAPAN; TSINGHUA UNIVERSITY, BEIJING, CHINA; UNIVERSITY OF HELSINKI, FINLAND; UNIVERSITY OF MILAN, ITALY; UNIVERSITY OF SASKATCHEWAN, SASKATOON, CANADA; UNIVERSITY OF SCIENCE AND TECHNOLOGY, HONG KONG, CHINA; UNIVERSITY OF TOKYO, JAPAN; UNIVERSITY OF TORONTO, CANADA; UNIVERSITY OF WURZBURG, GERMANY; UNIVERSITY OF ZURICH, SWITZERLAND; WELLCOME SANGER INSTITUTE, HINXTON, UNITED KINGDOM; AND YONSEI UNIVERSITY COLLEGE OF DENTISTRY, SEOUL, KOREA.

Schedule A (Form 990 or 990-EZ) 2019

Additional Data

Software ID:
Software Version:

- TIN:

Schedule B
(Form 990, 990-EZ,
or 990-PF)

Department of the Treasury
Internal Revenue Service

Schedule of Contributors

Attach to Form 990, 990-EZ, or 990-PF.

Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2019

Name of the organization

STOWERS INSTITUTE FOR MEDICAL RESEARCH

Employer identification number

20-2993509

Organization type (check one):

Filers of:

Section:

Form 990 or 990-EZ

501(c)( ) (enter number) organization

4947(a)(1) nonexempt charitable trust not treated as a private foundation

527 political organization

Form 990-PF

501(c)(3) exempt private foundation

4947(a)(1) nonexempt charitable trust treated as a private foundation

501(c)(3) taxable private foundation

Check if your organization is covered by the General Rule or a Special Rule.
Note: Only a section 501(c)(7), (8), or (10) organization can check boxes for both the General Rule and a Special Rule. See instructions.

General Rule

For an organization filing Form 990, 990-EZ, or 990-PF that received, during the year, contributions totaling $5,000 or more (in money or other property) from any one contributor. Complete Parts I and II. See instructions for determining a contributor's total contributions.

Special Rules

For an organization described in section 501(c)(3) filing Form 990 or 990-EZ that met the 33¹/3% support test of the regulations
under sections 509(a)(1) and 170(b)(1)(A)(vi), that checked Schedule A (Form 990 or 990-EZ), Part II, line 13, 16a, or 16b, and that received from any one contributor, during the year, total contributions of the greater of (1) $5,000 or (2) 2% of the amount on (i) Form 990, Part VIII, line 1h, or (ii) Form 990-EZ, line 1. Complete Parts I and II.

For an organization described in section 501(c)(7), (8), or (10) filing Form 990 or 990-EZ that received from any one contributor,
during the year, total contributions of more than $1,000 exclusively for religious, charitable, scientific, literary, or educational purposes, or for the prevention of cruelty to children or animals. Complete Parts I, II, and III.

For an organization described in section 501(c)(7), (8), or (10) filing Form 990 or 990-EZ that received from any one contributor,
during the year, contributions exclusively for religious, charitable, etc., purposes, but no such contributions totaled more than $1,000. If this box is checked, enter here the total contributions that were received during the year for an exclusively religious, charitable, etc., purpose. Don't complete any of the parts unless the General Rule applies to this organization because it received nonexclusively religious, charitable, etc., contributions totaling $5,000 or more during the year ......... Arrow Bullet

Caution: An organization that isn't covered by the General Rule and/or the Special Rules doesn't file Schedule B (Form 990,
990-EZ, or 990-PF), but it must answer “No” on Part IV, line 2, of its Form 990; or check the box on line H of its Form 990-EZ
or on its Form 990PF, Part I, line 2, to certify that it doesn't meet the filing requirements of Schedule B (Form 990,
990-EZ, or 990-PF).

For Paperwork Reduction Act Notice, see the Instructions
for Form 990, 990-EZ, or 990-PF.

Cat. No. 30613XSchedule B (Form 990, 990-EZ, or 990-PF) (2019)

Schedule B (Form 990, 990-EZ, or 990-PF) (2019) Page 2

Name of organization STOWERS INSTITUTE FOR MEDICAL RESEARCH

Part I Contributors	Contributors (see instructions). Use duplicate copies of Part I if additional space is needed.
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
RESTRICTED	,	$ RESTRICTED	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
Schedule B (Form 990, 990-EZ, or 990-PF) (2019)

Schedule B (Form 990, 990-EZ, or 990-PF) (2019)

Page 3

Name of organization STOWERS INSTITUTE FOR MEDICAL RESEARCH		Employer identification number 20-2993509

Part II	Noncash Property (see instructions). Use duplicate copies of Part II if additional space is needed.
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
Schedule B (Form 990, 990-EZ, or 990-PF) (2019)

Schedule B (Form 990, 990-EZ, or 990-PF) (2019)

Page 4


Name of organization STOWERS INSTITUTE FOR MEDICAL RESEARCH			Employer identification number 20-2993509
Part III Exclusively religious, charitable, etc., contributions to organizations described in section 501(c)(7), (8), or (10) that total more than $1,000 for the year from any one contributor. Complete columns (a) through (e) and the following line entry. For organizations completing Part III, enter the total of exclusively religious, charitable, etc., contributions of $1,000 or less for the year. (Enter this information once. See instructions.) $ Use duplicate copies of Part III if additional space is needed.

(a)
No. from Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a)
No. from Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a)
No. from Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a)
No. from Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

Schedule B (Form 990, 990-EZ, or 990-PF) (2019)

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE D
(Form 990)

Department of the Treasury
Internal Revenue Service

Supplemental Financial Statements

Complete if the organization answered "Yes," on Form 990,
Part IV, line 6, 7, 8, 9, 10, 11a, 11b, 11c, 11d, 11e, 11f, 12a, or 12b.
SchDMd Bullet

Attach to Form 990.
SchDMd Bullet

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2019

Open to Public Inspection

Name of the organization

STOWERS INSTITUTE FOR MEDICAL RESEARCH

Employer identification number

20-2993509

Part I

Organizations Maintaining Donor Advised Funds or Other Similar Funds or Accounts. Complete if the organization answered "Yes" on Form 990, Part IV, line 6.

		(a) Donor advised funds	(b) Funds and other accounts
1	Total number at end of year .........
2	Aggregate value of contributions to (during year)
3	Aggregate value of grants from (during year)
4	Aggregate value at end of year ........

Did the organization inform all donors and donor advisors in writing that the assets held in donor advised funds are the organization’s property, subject to the organization’s exclusive legal control? ............

Yes No

Did the organization inform all grantees, donors, and donor advisors in writing that grant funds can be used only for charitable purposes and not for the benefit of the donor or donor advisor, or for any other purpose conferring impermissible private benefit? ...................................

Yes No

Part II

Conservation Easements.
Complete if the organization answered "Yes" on Form 990, Part IV, line 7.

Purpose(s) of conservation easements held by the organization (check all that apply).

Preservation of land for public use (e.g., recreation or education) Preservation of an historically important land area

Protection of natural habitat Preservation of a certified historic structure

Preservation of open space

Complete lines 2a through 2d if the organization held a qualified conservation contribution in the form of a conservation easement on the last day of the tax year.


a	Total number of conservation easements ......................	2a
b	Total acreage restricted by conservation easements ....................	2b
c	Number of conservation easements on a certified historic structure included in (a) .....	2c
d	Number of conservation easements included in (c) acquired after 7/25/06, and not on a historic structure listed in the National Register ...	2d

Number of conservation easements modified, transferred, released, extinguished, or terminated by the organization during the
tax year SchDMd Bullet

Number of states where property subject to conservation easement is located SchDMd Bullet

Does the organization have a written policy regarding the periodic monitoring, inspection, handling of violations, and enforcement of the conservation easements it holds? ............

Yes No

Staff and volunteer hours devoted to monitoring, inspecting, handling of violations, and enforcing conservation easements during the year
SchDMd Bullet

Amount of expenses incurred in monitoring, inspecting, handling of violations, and enforcing conservation easements during the year
SchDMd Bullet

Does each conservation easement reported on line 2(d) above satisfy the requirements of section 170(h)(4)(B)(i) and section 170(h)(4)(B)(ii)? .............................

Yes No

In Part XIII, describe how the organization reports conservation easements in its revenue and expense statement, and
balance sheet, and include, if applicable, the text of the footnote to the organization’s financial statements that describes
the organization’s accounting for conservation easements.

Part III

Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets.
Complete if the organization answered "Yes" on Form 990, Part IV, line 8.

If the organization elected, as permitted under FASB ASC 958, not to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide, in Part XIII, the text of the footnote to its financial statements that describes these items.

If the organization elected, as permitted under FASB ASC 958, to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide the following amounts relating to these items:

(i)

Revenue included on Form 990, Part VIII, line 1 ......................... SchDMd Bullet

(ii)

Assets included in Form 990, Part X ............................... SchDMd Bullet

If the organization received or held works of art, historical treasures, or other similar assets for financial gain, provide the
following amounts required to be reported under FASB ASC 958 relating to these items:

Revenue included on Form 990, Part VIII, line 1 .......................... SchDMd Bullet

Assets included in Form 990, Part X ............................... SchDMd Bullet

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 52283D

Schedule D (Form 990) 2019

Page 2

Part III

Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets (continued)

Using the organization’s acquisition, accession, and other records, check any of the following that are a significant use of its collection items (check all that apply):

Public exhibition

Loan or exchange programs

Scholarly research

Other

Preservation for future generations

Provide a description of the organization’s collections and explain how they further the organization’s exempt purpose in
Part XIII.

During the year, did the organization solicit or receive donations of art, historical treasures or other similar
assets to be sold to raise funds rather than to be maintained as part of the organization’s collection?...

Yes No

Part IV

Escrow and Custodial Arrangements. Complete if the organization answered "Yes" on Form 990, Part IV, line 9, or reported an amount on Form 990, Part X, line 21.

Is the organization an agent, trustee, custodian or other intermediary for contributions or other assets not
included on Form 990, Part X? ....................................

Yes No


b	If "Yes," explain the arrangement in Part XIII and complete the following table:		Amount
c	Beginning balance .............................	1c
d	Additions during the year ............................	1d
e	Distributions during the year ..........................	1e
f	Ending balance ................................	1f

Did the organization include an amount on Form 990, Part X, line 21, for escrow or custodial account liability? ...

Yes No

If "Yes," explain the arrangement in Part XIII. Check here if the explanation has been provided in Part XIII ....

Part V

Endowment Funds.
Complete if the organization answered "Yes" on Form 990, Part IV, line 10.

		(a) Current year	(b) Prior year	(c) Two years back	(d) Three years back	(e) Four years back

1a	Beginning of year balance ....	120,721	550,240	626,653	39,191	0
b	Contributions ...	163,200	75,000	100,000	661,216	100,000
c	Net investment earnings, gains, and losses
d	Grants or scholarships ...
e	Other expenditures for facilities and programs ...	77,543	504,519	176,413	73,754	60,809
f	Administrative expenses ....
g	End of year balance ......	206,378	120,721	550,240	626,653	39,191

Provide the estimated percentage of the current year end balance (line 1g, column (a)) held as:

Board designated or quasi-endowment SchDMd Bullet

Permanent endowment SchDMd Bullet

Term endowment SchDMd Bullet

100.000 %

The percentages on lines 2a, 2b, and 2c should equal 100%.

Are there endowment funds not in the possession of the organization that are held and administered for the
organization by:

Yes

(i) Unrelated organizations .................

3a(i)

(ii) Related organizations .................

3a(ii)

If "Yes" on 3a(ii), are the related organizations listed as required on Schedule R? .........

Describe in Part XIII the intended uses of the organization's endowment funds.

Part VI

Land, Buildings, and Equipment.
Complete if the organization answered "Yes" on Form 990, Part IV, line 11a. See Form 990, Part X, line 10.

Description of property		(a) Cost or other basis (investment)	(b) Cost or other basis (other)	(c) Accumulated depreciation	(d) Book value

1a	Land .....	3,400,000		3,400,000
b	Buildings ....	232,820,072	115,655,967	117,164,105
c	Leasehold improvements
d	Equipment ....	95,244,723	79,072,169	16,172,554
e	Other .....	1,590,220		1,590,220
Total. Add lines 1a through 1e. (Column (d) must equal Form 990, Part X, column (B), line 10(c).)..				138,326,879

Schedule D (Form 990) 2019

Page 3

Part VII

InvestmentsOther Securities.
Complete if the organization answered "Yes" on Form 990, Part IV, line 11b. See Form 990, Part X, line 12.

(a) Description of security or category (including name of security)	(b) Book value	(c) Method of valuation: Cost or end-of-year market value
(1) Financial derivatives.........
(2) Closely-held equity interests........
(3)Other
(B)
(C)
(D)
(E)
(F)
(G)
(H)
(I)
Total. (Column (b) must equal Form 990, Part X, col. (B) line 12.)

Part VIII

InvestmentsProgram Related. Complete if the organization answered 'Yes' on Form 990, Part IV, line 11c. See Form 990, Part X, line 13.

(a) Description of investment	(b) Book value	(c) Method of valuation: Cost or end-of-year market value

(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
Total. (Column (b) must equal Form 990, Part X, col.(B) line 13.)

Part IX

Other Assets.
Complete if the organization answered 'Yes' on Form 990, Part IV, line 11d. See Form 990, Part X, line 15.

(a) Description				(b) Book value
(1)ANNUITY REC. FROM AFFILIATE				85,435,085
(2)OTHER RECEIVABLES				77,041
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
Total. (Column (b) must equal Form 990, Part X, col.(B) line 15.)...........				85,512,126

Part X

Other Liabilities.
Complete if the organization answered 'Yes' on Form 990, Part IV, line 11e or 11f. See Form 990, Part X, line 25.

1.(a) Description of liability	(b) Book value
(1) Federal income taxes	0
(5)
(6)
(7)
(8)
(9)
Total. (Column (b) must equal Form 990, Part X, col.(B) line 25.)	91,121,685
2. Liability for uncertain tax positions. In Part XIII, provide the text of the footnote to the organization's financial statements that reports the organization's liability for uncertain tax positions under FIN 48 (ASC 740). Check here if the text of the footnote has been provided in Part XIII

Schedule D (Form 990) 2019

Page 4

Part XI Reconciliation of Revenue per Audited Financial Statements With Revenue per Return. Complete if the organization answered 'Yes' on Form 990, Part IV, line 12a.
1	Total revenue, gains, and other support per audited financial statements .......		1
2	Amounts included on line 1 but not on Form 990, Part VIII, line 12:
a	Net unrealized gains (losses) on investments ....	2a
b	Donated services and use of facilities .........	2b
c	Recoveries of prior year grants ...........	2c
d	Other (Describe in Part XIII.) ............	2d
e	Add lines 2a through 2d .....................		2e
3	Subtract line 2e from line 1..................		3
4	Amounts included on Form 990, Part VIII, line 12, but not on line 1:
a	Investment expenses not included on Form 990, Part VIII, line 7b .	4a
b	Other (Describe in Part XIII.) ...........	4b
c	Add lines 4a and 4b....................		4c
5	Total revenue. Add lines 3 and 4c. (This must equal Form 990, Part I, line 12.) ......		5

Part XII Reconciliation of Expenses per Audited Financial Statements With Expenses per Return. Complete if the organization answered 'Yes' on Form 990, Part IV, line 12a.
1	Total expenses and losses per audited financial statements ...........		1
2	Amounts included on line 1 but not on Form 990, Part IX, line 25:
a	Donated services and use of facilities .........	2a
b	Prior year adjustments ............	2b
c	Other losses ................	2c
d	Other (Describe in Part XIII.) ............	2d
e	Add lines 2a through 2d....................		2e
3	Subtract line 2e from line 1...................		3
4	Amounts included on Form 990, Part IX, line 25, but not on line 1:
a	Investment expenses not included on Form 990, Part VIII, line 7b ..	4a
b	Other (Describe in Part XIII.) ............	4b
c	Add lines 4a and 4b.....................		4c
5	Total expenses. Add lines 3 and 4c. (This must equal Form 990, Part I, line 18.) ......		5

Part XIII

Supplemental Information

Provide the descriptions required for Part II, lines 3, 5, and 9; Part III, lines 1a and 4; Part lV, lines 1b and 2b; Part V, line 4; Part X, line 2; Part XI, lines 2d and 4b; and Part XII, lines 2d and 4b. Also complete this part to provide any additional information.

Return Reference	Explanation
PART V, LINE 4:	THE ENDOWMENT IS FROM A SINGLE DONOR TO CONTRIBUTE FUNDING TOWARDS AN ESTABLISHED LECTURE SERIES PROGRAM WHERE SIMR HOSTS SCIENCE SPEAKERS FROM OTHER RESEARCH INSTITUTIONS AND UNIVERSITIES TO ENCOURAGE COLLABORATIVE SCIENCE OPPORTUNITIES WITH TOP SCIENTISTS FROM AROUND THE WORLD.
PART X, LINE 2:	FIN 48 FINANCIAL STATEMENT FOOTNOTE FROM THE CONSOLIDATED STATEMENTS OF STOWERS INSTITUTE FOR MEDICAL RESEARCH (THE INSTITUTE) IS AS FOLLOWS: THE INSTITUTE RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT OF BEING SUSTAINED. RECOGNIZED INCOME TAX POSITIONS ARE MEASURED AT THE LARGEST AMOUNT THAT IS GREATER THAN 50% LIKELY OF BEING REALIZED.

Schedule D (Form 990) 2019

Additional Data

Software ID:
Software Version:

- TIN:

Schedule J
(Form 990)

Department of the Treasury
Internal Revenue Service

Compensation Information

For certain Officers, Directors, Trustees, Key Employees, and Highest
Compensated Employees
SchJMediumBullet

Complete if the organization answered "Yes" on Form 990, Part IV, line 23.
SchJMediumBullet

Attach to Form 990.
SchJMediumBullet

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2019

Open to Public Inspection

Name of the organization

STOWERS INSTITUTE FOR MEDICAL RESEARCH

Employer identification number

20-2993509

Part I

Questions Regarding Compensation

Yes

Check the appropiate box(es) if the organization provided any of the following to or for a person listed on Form
990, Part VII, Section A, line 1a. Complete Part III to provide any relevant information regarding these items.

First-class or charter travel Housing allowance or residence for personal use

Travel for companions Payments for business use of personal residence

Tax idemnification and gross-up payments Health or social club dues or initiation fees

Discretionary spending account Personal services (e.g., maid, chauffeur, chef)

If any of the boxes on Line 1a are checked, did the organization follow a written policy regarding payment or reimbursement or provision of all of the expenses described above? If "No," complete Part III to explain .........

Yes

Did the organization require substantiation prior to reimbursing or allowing expenses incurred by all
directors, trustees, officers, including the CEO/Executive Director, regarding the items checked on Line 1a? ..

Yes

Indicate which, if any, of the following the filing organization used to establish the compensation of the
organization's CEO/Executive Director. Check all that apply. Do not check any boxes for methods
used by a related organization to establish compensation of the CEO/Executive Director, but explain in Part III.

Compensation committee Written employment contract

Independent compensation consultant Compensation survey or study

Form 990 of other organizations Approval by the board or compensation committee

During the year, did any person listed on Form 990, Part VII, Section A, line 1a, with respect to the filing organization or a related organization:

Receive a severance payment or change-of-control payment? .............

Participate in, or receive payment from, a supplemental nonqualified retirement plan? .........

Participate in, or receive payment from, an equity-based compensation arrangement? .........

If "Yes" to any of lines 4a-c, list the persons and provide the applicable amounts for each item in Part III.

Only 501(c)(3), 501(c)(4), and 501(c)(29) organizations must complete lines 5-9.

For persons listed on Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any
compensation contingent on the revenues of:

The organization? ....................

Yes

Any related organization? .......................

If "Yes," on line 5a or 5b, describe in Part III.

For persons listed on Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any
compensation contingent on the net earnings of:

The organization? ..................

Any related organization? ......................

If "Yes," on line 6a or 6b, describe in Part III.

For persons listed on Form 990, Part VII, Section A, line 1a, did the organization provide any nonfixed
payments not described in lines 5 and 6? If "Yes," describe in Part III ............

Were any amounts reported on Form 990, Part VII, paid or accured pursuant to a contract that was
subject to the initial contract exception described in Regulations section 53.4958-4(a)(3)? If "Yes," describe
in Part III ..........................

If "Yes" on line 8, did the organization also follow the rebuttable presumption procedure described in Regulations section 53.4958-6(c)? .........................

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50053T

Schedule J (Form 990) 2019

Page 2

Part II

Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees. Use duplicate copies if additional space is needed.

For each individual whose compensation must be reported on Schedule J, report compensation from the organization on row (i) and from related organizations, described in the
instructions, on row (ii). Do not list any individuals that are not listed on Form 990, Part VII.
Note. The sum of columns (B)(i)-(iii) for each listed individual must equal the total amount of Form 990, Part VII, Section A, line 1a, applicable column (D) and (E) amounts for that individual.

(A) Name and Title		(B) Breakdown of W-2 and/or 1099-MISC compensation			(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)	(F) Compensation in column (B) reported as deferred on prior Form 990
(A) Name and Title		(i) Base compensation	(ii) Bonus & incentive compensation	(iii) Other reportable compensation	(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)
1DAVID A WELTE DIRECTOR/SECRETARY	(i) (ii)	0 ------------- 1,368,976	0 ------------- 0	0 ------------- 56,058	0 ------------- 42,000	0 ------------- 28,740	0 ------------- 1,495,774	0 ------------- 0
2RODERICK L STURGEON DIRECTOR/CFO	(i) (ii)	0 ------------- 1,597,472	0 ------------- 0	0 ------------- 107,511	0 ------------- 42,000	0 ------------- 22,605	0 ------------- 1,769,588	0 ------------- 0
3DAVID M CHAO DIRECTOR/PRESIDENT/CEO	(i) (ii)	1,360,250 ------------- 0	0 ------------- 0	9,921 ------------- 0	42,000 ------------- 0	1,446 ------------- 0	1,413,617 ------------- 0	0 ------------- 0
4ROBERT E KRUMLAUF - TO 72019 DIR/SCIENTIFIC DIR EMERITUS	(i) (ii)	437,532 ------------- 0	0 ------------- 0	193,875 ------------- 0	42,000 ------------- 0	21,105 ------------- 0	694,512 ------------- 0	0 ------------- 0
5RICHARD W BROWN DIRECTOR/CHAIR	(i) (ii)	0 ------------- 2,516,009	0 ------------- 0	0 ------------- 27,489	0 ------------- 42,000	0 ------------- 19,830	0 ------------- 2,605,328	0 ------------- 0
6ALEJANDRO SANCHEZ ALVARADO DIR/SCIENTIFIC DIR FROM 7/2019	(i) (ii)	153,849 ------------- 0	0 ------------- 0	361 ------------- 0	16,350 ------------- 0	401 ------------- 0	170,961 ------------- 0	0 ------------- 0
7BRENT KREIDER CHIEF OPERATING OFFICER	(i) (ii)	0 ------------- 607,808	0 ------------- 0	0 ------------- 8,844	0 ------------- 0	0 ------------- 25,223	0 ------------- 641,875	0 ------------- 0
8RONALD C CONAWAY INVESTIGATOR	(i) (ii)	309,629 ------------- 0	0 ------------- 0	3,564 ------------- 0	42,000 ------------- 0	1,446 ------------- 0	356,639 ------------- 0	0 ------------- 0
9JOAN W CONAWAY INVESTIGATOR	(i) (ii)	307,562 ------------- 0	0 ------------- 0	3,564 ------------- 0	42,000 ------------- 0	19,863 ------------- 0	372,989 ------------- 0	0 ------------- 0
10JERRY L WORKMAN INVESTIGATOR	(i) (ii)	369,979 ------------- 0	0 ------------- 0	3,564 ------------- 0	42,000 ------------- 0	12,043 ------------- 0	427,586 ------------- 0	0 ------------- 0
11R SCOTT HAWLEY INVESTIGATOR	(i) (ii)	368,456 ------------- 0	0 ------------- 0	4,191 ------------- 0	42,000 ------------- 0	19,908 ------------- 0	434,555 ------------- 0	0 ------------- 0
12LINHENG LI INVESTIGATOR	(i) (ii)	272,474 ------------- 0	0 ------------- 0	3,564 ------------- 0	40,871 ------------- 0	1,446 ------------- 0	318,355 ------------- 0	0 ------------- 0

Schedule J (Form 990) 2019

Page 3

Part III

Supplemental Information

Provide the information, explanation, or descriptions required for Part I, lines 1a, 1b, 3, 4a, 4b, 4c, 5a, 5b, 6a, 6b, 7, and 8, and for Part II. Also complete this part for any additional information.

Return Reference	Explanation
PART I, LINE 1A:	SIMR HAS A WRITTEN EMPLOYMENT AGREEMENT WITH DAVID M. CHAO, WHICH PROVIDES FOR TAXABLE TERM LIFE BENEFITS AND FOR HIM TO RECEIVE TAX GROSS-UP PAYMENTS SUFFICIENT TO COVER THE TAXES ON THESE BENEFITS.
PART I, LINE 1B:	SIMR PROVIDED THE BENEFITS DESCRIBED IN RESPONSE TO LINE 1A PURSUANT TO WRITTEN EMPLOYMENT CONTRACTS THAT WAS APPROVED BY SIMR'S GOVERNING BOARD. SEE RESPONSE TO FORM 990, PART VI, SECTION B, LINE 15, FOR ADDITIONAL PROCESSES RELATED TO DETERMINING EXECUTIVE COMPENSATION.
PART I, LINE 5A:	SIMR MADE A PAYMENT OF $188,931 TO ROBERT E. KRUMLAUF, SCIENTIFIC DIRECTOR. THIS PAYMENT REPRESENTS THE PORTION OF THE NET ROYALTIES RECEIVED BY SIMR FOR LICENSED SCIENTIFIC DISCOVERY TECHNOLOGY THAT IS PAYABLE TO ROBERT E. KRUMLAUF, PH.D., FOR HIS PARTICIPATION IN THE DISCOVERY.
PART II, LINES 4 AND 6:	ROBERT KRUMLAUF SERVED AS SIMR'S SCIENTIFIC DIRECTOR THROUGH JUNE 30, 2019, AFTER WHICH HE BECAME SCIENTIFIC DIRECTOR EMERITUS. ALEJANDRO SANCHEZ ALVARADO BECAME SIMR'S SCIENTIFIC DIRECTOR ON JULY 1, 2019.

Schedule J (Form 990) 2019

Additional Data

Software ID:
Software Version:

- TIN:

Schedule L
(Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service

Transactions with Interested Persons

Complete if the organization answered "Yes" on Form 990, Part IV, lines 25a, 25b, 26, 27, 28a, 28b, or 28c, or Form 990-EZ, Part V, line 38a or 40b.
MediumBullet

Attach to Form 990 or Form 990-EZ.
MediumBullet

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2019

Open to Public Inspection

Name of the organization

STOWERS INSTITUTE FOR MEDICAL RESEARCH

Employer identification number

20-2993509

Part I

Excess Benefit Transactions (section 501(c)(3), section 501(c)(4), and section 501(c)(29) organizations only).
Complete if the organization answered "Yes" on Form 990, Part IV, line 25a or 25b, or Form 990-EZ, Part V, line 40b.

1(a) Name of disqualified person	(c) Description of transaction	(d) Corrected?
1(a) Name of disqualified person	(c) Description of transaction	Yes	No

Enter the amount of tax incurred by the organization managers or disqualified persons during the year under section 4958. ........................... Bullet Image

Enter the amount of tax, if any, on line 2, above, reimbursed by the organization ........ Bullet Image

Part II

Loans to and/or From Interested Persons.
Complete if the organization answered "Yes" on Form 990-EZ, Part V, line 38a, or Form 990, Part IV, line 26; or if the organization reported an amount on Form 990, Part X, line 5, 6, or 22

(a) Name of interested person	(b) Relationship with organization	(c) Purpose of loan	(d) Loan to or from the organization?		(e) Original principal amount	(f) Balance due	(g) In default?		(h) Approved by board or committee?		(i) Written agreement?
(a) Name of interested person	(b) Relationship with organization	(c) Purpose of loan	To	From	(e) Original principal amount	(f) Balance due	Yes	No	Yes	No	Yes	No






Total ............... $

Part III

Grants or Assistance Benefiting Interested Persons.
Complete if the organization answered "Yes" on Form 990, Part IV, line 27.

(a) Name of interested person	(b) Relationship between interested person and the organization	(c) Amount of assistance	(d) Type of assistance	(e) Purpose of assistance

For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ.

Cat. No. 50056A

Schedule L (Form 990 or 990-EZ) 2019

Page 2

Part IV

Business Transactions Involving Interested Persons.
Complete if the organization answered "Yes" on Form 990, Part IV, line 28a, 28b, or 28c.

(a) Name of interested person	(b) Relationship between interested person and the organization	(c) Amount of transaction	(d) Description of transaction	(e) Sharing of organization's revenues?
(a) Name of interested person		(c) Amount of transaction	(d) Description of transaction	Yes	No
(1) JULIA ZEITLINGER PHD	SEE PART V	263,391	EMPLOYEE OF SIMR		No
(2) LEANNE WIEDEMANN PHD	SEE PART V	267,756	EMPLOYEE OF SIMR		No
(3) TATJANA PIOTROWSKI PHD	SEE PART V	251,012	EMPLOYEE OF SIMR		No

Part V

Supplemental Information
Provide additional information for responses to questions on Schedule L (see instructions).

Return Reference

Explanation

PART IV, LINES (1) , (2) & (3):

JULIA ZEITLINGER, PH.D, IS THE SPOUSE OF DAVID M. CHAO, PRESIDENT OF SIMR. MS. ZEITLINGER IS AN ASSOCIATE INVESTIGATOR AT SIMR. MS. ZEITLINGER'S PREVIOUS EMPLOYMENT BEFORE SIMR WAS WITH THE WHITEHEAD INSTITUTE FOR MEDICAL RESEARCH WHERE SHE WAS THE RECIPIENT OF A PREDOCTORAL FELLOWSHIP FROM THE HUMAN FRONTIER SCIENCE PROGRAM. LEANNE WIEDMANN, PH.D, IS THE SPOUSE OF ROBERT KRUMLAUF, SCIENTIFIC DIRECTOR EMERITUS OF SIMR. MS. WIEDEMANN PERFORMS INDEPENDENT SCIENCE RESEARCH AT SIMR AND IS CONCURRENTLY A PROFESSOR AT THE UNIVERSITY OF KANSAS MEDICAL CENTER IN THE DEPARTMENT OF PATHOLOGY AND LABORATORY MEDICINE. TATJANA PIOTROWSKI, PH.D, IS THE SPOUSE OF ALEJANDRO SANCHEZ ALVARADO, DIRECTOR AND SCIENTIFIC DIRECTOR OF SIMR AS OF JULY 2019. MS. PIOTROWSKI IS AN INVESTIGATOR AT SIMR. HER PREVIOUS EMPLOYMENT BEFORE SIMR WAS WITH THE UNIVERSITY OF UTAH'S SCHOOL OF MEDICINE WHERE SHE WAS AN ASSOCIATE PROFESSOR IN THE DEPARTMENT OF NEUROBIOLGOY AND ANATOMY.

Schedule L (Form 990 or 990-EZ) 2019

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE M
(Form 990)

Department of the Treasury

Internal Revenue Service

Noncash Contributions

Complete if the organizations answered "Yes" on Form 990, Part IV, lines 29 or 30.
Right pointing arrow large image

Attach to Form 990.
Right pointing arrow large image

Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2019

Open to Public Inspection

Name of the organization

STOWERS INSTITUTE FOR MEDICAL RESEARCH

Employer identification number

20-2993509

Part I

Types of Property

	(a) Check if applicable	(b) Number of contributions or items contributed	(c) Noncash contribution amounts reported on Form 990, Part VIII, line 1g	(d) Method of determining noncash contribution amounts
1 Art—Works of art ....
2 Art—Historical treasures .
3 Art—Fractional interests ..
4 Books and publications ..
5 Clothing and household goods .......
6 Cars and other vehicles ..
7 Boats and planes ....
8 Intellectual property ...
9 Securities—Publicly traded .	X	3	63,100,000	FAIR MARKET VALUE
10 Securities—Closely held stock .
11 Securities—Partnership, LLC, or trust interests ....
12 Securities—Miscellaneous ..
13 Qualified conservation contribution—Historic structures .....
14 Qualified conservation contribution—Other ...
15 Real estate—Residential .
16 Real estate—Commercial ..
17 Real estate—Other ...
18 Collectibles .....
19 Food inventory ...
20 Drugs and medical supplies .
21 Taxidermy ......
22 Historical artifacts ....
23 Scientific specimens ..
24 Archeological artifacts ...
25 Other ( )
26 Other ( )
27 Other ( )
28 Other ( )

Number of Forms 8283 received by the organization during the tax year for contributions
for which the organization completed Form 8283, Part IV, Donee Acknowledgement

Yes

30a

During the year, did the organization receive by contribution any property reported in Part I, lines 1 through 28, that it must hold for at least three years from the date of the initial contribution, and which isn't required to be used for exempt purposes for the entire holding period? ...................

30a

If "Yes," describe the arrangement in Part II.

Does the organization have a gift acceptance policy that requires the review of any nonstandard contributions?

Yes

32a

Does the organization hire or use third parties or related organizations to solicit, process, or sell noncash

contributions? ..........................

32a

If "Yes," describe in Part II.

If the organization didn't report an amount in column (c) for a type of property for which column (a) is checked,

describe in Part II.

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 51227J

Schedule M (Form 990) (2019)

Page 2

Part IISupplemental Information. Provide the information required by Part I, lines 30b, 32b, and 33, and whether the organization is reporting in Part I, column (b), the number of contributions, the number of items received, or a combination of both. Also complete this part for any additional information.

Return Reference	Explanation
PART I, COLUMN B:	THE AMOUNTS SHOWN IN PART I, COLUMN (B) FOR "NUMBER OF CONTRIBUTIONS" REPRESENTS THE TOTAL NUMBER OF CONTRIBUTIONS AND NOT NECESSARILY THE TOTAL NUMBER OF ITEMS CONTRIBUTED.

Schedule M (Form 990) (2019)

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE O
(Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service

Supplemental Information to Form 990 or 990-EZ

Complete to provide information for responses to specific questions on
Form 990 or 990-EZ or to provide any additional information.
MediumBullet

Attach to Form 990 or 990-EZ.
MediumBullet

Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2019

Open to Public
Inspection

Name of the organization

STOWERS INSTITUTE FOR MEDICAL RESEARCH

Employer identification number

20-2993509

Return Reference	Explanation
PART III, LINE 1:	THE STOWERS INSTITUTE FOR MEDICAL RESEARCH ("SIMR") PERFORMS MEDICAL RESEARCH IN THE PUBLIC INTEREST WITH THE GOAL OF EXPANDING THE UNDERSTANDING OF FUNDAMENTAL PROCESSES IN LIVING CELLS AND IMPROVING LIFE'S QUALITY THROUGH INNOVATIVE APPROACHES TO THE CAUSES, TREATMENT, AND PREVENTION OF DISEASE. PART III, LINE 4: SIMR'S ACCOMPLISHMENTS ARE DESCRIBED AT THE END OF SCHEDULE O. PART VI, LINE 2: VIRGINIA G. STOWERS, JONATHAN THOMAS, RICHARD W. BROWN, DAVID A. WELTE, DAVID M. CHAO, ALBERZINE FREEMAN, AND ALEJANDRO SANCHEZ ALVARADO, ALL DIRECTORS OF SIMR, HAVE A BUSINESS RELATIONSHIP. JONATHAN THOMAS, RICHARD W. BROWN, DAVID A. WELTE, DAVID M. CHAO, RODERICK L. STURGEON, AND ALBERZINE FREEMAN, DIRECTORS OF SIMR, AND BRENT KREIDER, OFFICER OF SIMR, HAVE A BUSINESS RELATIONSHIP. DAVID A. WELTE, RICHARD W. BROWN, AND RODERICK L. STURGEON, DIRECTORS OF SIMR, AND BRENT KREIDER, OFFICER OF SIMR, HAVE A BUSINESS RELATIONSHIP. PART VI, LINE 11B: THE DATA AND INFORMATION NECESSARY TO PREPARE SIMR'S FORM 990 WAS COMPILED BY SIMR'S ACCOUNTING DEPARTMENT AND THEN REVIEWED BY THE INSTITUTE'S S TAX ATTORNEY AT BRYAN CAVE LEIGHTON PAISNER, LLP. PRICEWATERHOUSECOOPERS ("PWC"), THE INSTITUTE'S EXTERNAL TAX PREPARERS, USED THIS INFORMATION TO PREPARE THE FORM 990. THE COMPLETED FORM 990, INCLUDING REQUIRED SCHEDULES, IS REVIEWED BY THE OFFICERS OF SIMR BEFORE IT IS FILED WITH THE IRS. AFTER THE PREPARATION AND REVIEW PROCESS DESCRIBED ABOVE, THE FORM 990, INCLUDING REQUIRED SCHEDULES, IS PROVIDED TO EACH VOTING MEMBER OF THE ORGANIZATION'S BOARD BEFORE IT IS FILED WITH THE IRS. PART VI, LINE 12C: SIMR HAS ADOPTED A "CONFLICTS OF INTEREST AND DIRECTOR INDEPENDENCE POLICY". EACH DIRECTOR, OFFICER, AND ALL OTHER PERSONS IN A POSITION TO EXERCISE SUBSTANTIAL INFLUENCE OVER DECISIONS OF SIMR ARE REQUIRED TO ANNUALLY COMPLETE AND SIGN A DISCLOSURE STATEMENT THAT IS PART OF THE POLICY. A COVERED PERSON MUST ALSO DISCLOSE THE EXISTENCE OF A POTENTIAL CONFLICT AND ALL MATERIAL FACTS TO THE GOVERNING BOARD AS SOON AS THE PERSON HAS KNOWLEDGE THAT A POTENTIAL CONFLICT MIGHT EXIST. SIMR CONDUCTS PERIODIC AND ADHOC REVIEWS OF TRANSACTIONS AND AGREEMENTS TO ENSURE THAT IT ENGAGES ONLY IN ACTIVITIES THAT ARE CONSISTENT WITH ITS TAX-EXEMPT PURPOSE. FORM 990, PART VI, LINE 15A: THE COMPENSATION FOR DAVID CHAO, THE PRESIDENT AND CEO OF SIMR, WAS ESTABLISHED PURSUANT TO THE PROCEDURES OF TREAS. REG. SECTION 53.4958- 6, INCLUDING (1) REVIEW AND APPROVAL BY SIMR'S COMPENSATION COMMITTEE COMPRISED OF INDEPENDENT PERSONS, (2) RELYING ON COMPARABILITY DATA, INCLUDING DATA PREPARED BY A NATIONALLY KNOWN COMPENSATION CONSULTANT REGARDING COMPARABLE SALARY AND BENEFITS FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS, AND (3) CONTEMPORANEOUS DOCUMENTATION AND RECORD KEEPING OF THE DELIBERATION AND DECISIONS REGARDING THE COMPENSATION ARRANGEMENT. THIS PROCESS WAS LAST UNDERTAKEN IN 2019. PART VI, LINE 19: SIMR'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. PART VII, SECTION A, COLUMN B: DAVID M. CHAO, OFFICER OF SIMR, AND R. SCOTT HAWLEY, EMPLOYEE OF SIMR, ALSO PERFORM SUPPORT SERVICES FOR ONE OR MORE OF THE RELATED ORGANIZATIONS DISCLOSED IN SCHEDULE R. THESE SERVICES ARE PERFORMED IN THEIR ROLE AS SIMR EMPLOYEES AND SIMR IS REIMBURSED BY THE RELATED ORGANIZATIONS. PART VII, SECTION B: SIMR RECEIVES INVESTMENT MANAGEMENT SERVICES FROM AMERICAN CENTURY INVESTMENTS ("ACI"). ACI IS A WHOLLY OWNED SUBSIDIARY OF AMERICAN CENTURY COMPANIES, INC. ("ACCI"). IN SELECTING ACI TO MANAGE ITS LIQUID INVESTMENTS, SIMR NOT ONLY CHOSE A HIGH QUALITY MUTUAL FUND COMPANY WITH AN OUTSTANDING TRACK RECORD, BUT ALSO PLACED ITS LIQUID INVESTMENTS IN A COMPANY IN WHICH IT OWNS STOCK AND RECEIVES DIVIDENDS. SIMR PAYS ACI THE SAME ADMINISTRATIVE FEES FOR THESE SERVICES AS ANY ARMS-LENGTH INVESTOR.THOSE INVESTMENT FEES FOR A SHARED INVESTMENT POOL ARE PAID BY ITS SUPPORTING ORGANIZATION, STOWERS RESOURCE MANAGEMENT. PART XI, LINE 9: OTHER CHANGES IN NET ASSETS INCLUDE THE FOLLOWING: CHANGE IN ANNUITY RECEIVABLE, NET ($234,502)
PART III, LINE 4A	2019 PROGRAM SERVICE ACCOMPLISHMENTS THE STOWERS INSTITUTE FOR MEDICAL RESEARCH ("SIMR") IS A PRIVATE, NONPROFIT MEDICAL RESEARCH ORGANIZATION. SIMR WAS FOUNDED IN 1994 BY JIM AND VIRGINIA STOWERS, WHO EACH SURVIVED A BOUT WITH CANCER AND SUBSEQUENTLY DEDICATED THEIR FORTUNE TO SUPPORTING BASIC RESEARCH IN CELL AND MOLECULAR BIOLOGY THAT WILL PROVIDE LONG-TERM SOLUTIONS TO HUMAN DISEASES. SIMR CONDUCTS BASIC BIOMEDICAL RESEARCH IN THE PUBLIC INTEREST THAT WILL ULTIMATELY PROVIDE A GREATER UNDERSTANDING OF THE GENES AND PROTEINS THAT CONTROL HOW CELLS IN OUR BODIES MULTIPLY, FORM TISSUES, AND DIE. STUDYING THE BASIC BIOLOGY OF CELLS ENABLES SCIENTISTS TO DISCOVER HOW GENES CAUSE MANY DISEASES, INCLUDING CANCER, BIRTH DEFECTS, AND DEMENTIA. HISTORY HAS SHOWN THAT BASIC MEDICAL RESEARCH IS OFTEN A KEY FIRST STEP IN THE DEVELOPMENT OF NEW TREATMENTS, CURES, AND PREVENTIONS FOR MANY HUMAN DISEASES. 2019 NOTABLE RESEARCH RESULTS IN 2019, SIMR RESEARCH TEAMS MADE DISCOVERIES MERITING PUBLICATION IN LEADING PEER-REVIEWED SCIENTIFIC JOURNALS - 74 ORIGINAL RESEARCH PAPERS IN ALL. SIMR RESEARCH TEAMS ALSO PRODUCED 34 OTHER PUBLICATIONS INCLUDING REVIEWS, COMMENTARIES, BOOK CHAPTERS, AND BOOKS. SOME OF THE HIGHLIGHTS AMONG THESE PAPERS AND OTHER ADVANCES INVOLVING STOWERS RESEARCH INCLUDE THE FOLLOWING: THE KRUMLAUF LAB HELPED LAY THE GROUNDWORK FOR A NEW APPROACH TO TREATING OSTEOPOROSIS WITH AN UNEXPECTED DISCOVERY MADE NEARLY TWO DECADES AGO. AFTER UNCOVERING A MECHANISM THAT CONTROLS BONE GROWTH, THEIR WORK WAS PATENTED AND THE INTELLECTUAL PROPERTY LICENSED TO AMGEN IN 2005. AMGEN USED THAT FINDING AS WELL AS OTHERS' RESEARCH ABOUT BONE GROWTH TO DEVELOP A NEW DRUG, ROMOSOZUMAB. TWO PHASE 3 CLINICAL TRIALS SHOWED A SIGNIFICANT REDUCTION OF FRACTURES. THE DRUG ALSO INCREASED BONE DENSITY IN THE SPINES OF STUDY PARTICIPANTS BY AROUND 15%. ROMOSOZUMAB, THE FIRST NEW DRUG AIDED BY RESEARCH FROM SIMR, WAS APPROVED BY THE US FOOD AND DRUG ADMINISTRATION IN JANUARY 2019. THE LI LAB PUBLISHED A STUDY DESCRIBING HOW BLOOD-FORMING ADULT STEM CELLS REPOPULATE AFTER CHEMOTHERAPY. THESE CELLS, CALLED "RESERVE" HEMATOPOIETIC STEM CELLS, RESIDE IN BONE MARROW. THEY ARE RESPONSIBLE FOR REGENERATING THE BODY'S BLOOD SUPPLY, REPOPULATING AFTER CHEMOTHERAPY OR INJURY DEPLETES THEIR NUMBERS. THE FINDINGS MAY OPEN NEW AVENUES FOR TREATING BLOOD DISEASES LIKE LEUKEMIA AND AUTOIMMUNE DISORDERS. THE STUDY WAS PUBLISHED ONLINE JANUARY 15, 2019, IN CELL REPORTS. THE WASHBURN LAB CREATED A TOPOLOGICAL SCORING (TOPS) ALGORITHM, WHICH ALLOWS SCIENTISTS TO LOOK AT BIG SETS OF DATA IN NEW WAYS. THIS HELPS SCIENTISTS UNCOVER MORE DETAILS ABOUT HOW PROTEINS INTERACT AND UNDERSTAND HOW CERTAIN ACTIVITIES ON THE CELLULAR LEVEL HAPPEN. THE REPORT WAS PUBLISHED IN THE MARCH 8, 2019, ISSUE OF NATURE COMMUNICATIONS. THE BAZZINI LAB SHOWED THAT IN HUMAN CELL LINES, RIBOSOMES PLAY AN ACTIVE ROLE IN REGULATING MRNAS - THE MESSAGES THAT RIBOSOMES READ TO MAKE PROTEINS. THE STUDY ALSO PROVIDES EVIDENCE FOR ANOTHER LAYER OF INFORMATION WITHIN THE MESSAGES THAT CAN AFFECT MRNA LEVELS AND STABILITY. UNDERSTANDING THE REGULATORY FUNCTION OF RIBOSOMES IN MODULATING GENE EXPRESSION IN HUMAN CELLS CAN PROVIDE INSIGHT ABOUT CAUSES OF GENE MISREGULATION, WHICH CAN SOMETIMES LEAD TO HUMAN DISEASES. THE FINDINGS WERE PUBLISHED ONLINE APRIL 23, 2019, IN ELIFE. THE GERTON LAB UNCOVERED AN ANSWER TO A CENTURIES-OLD QUESTION OF HOW CONNECTIONS BETWEEN PARTICULAR HUMAN CHROMOSOMES MIGHT BE BUILT. THESE INTER-CHROMOSOMAL CONNECTIONS ARE COMPOSED OF RIBOSOMAL DNA WITH A SHARED SEQUENCE. THE FINDINGS SUGGEST THAT THE CONNECTIONS ARE CONTROLLED BY THE PROXIMITY OF THE CHROMOSOMES IN THREE-DIMENSIONAL SPACE AND THEIR TRANSCRIPTION, WHICH TOGETHER ALLOW CHROMOSOMES TO BUMP INTO EACH OTHER AND BECOME INTERLOCKED. THE FINDINGS COULD PROVIDE CLUES ABOUT THE ORIGINS OF CHROMOSOMAL FUSIONS ASSOCIATED WITH INFERTILITY AND DEVELOPMENTAL DISORDERS IN HUMANS. THE ARTICLE WAS PUBLISHED JULY 23, 2019, IN THE JOURNAL OF CELL BIOLOGY. THE GIBSON LAB PUBLISHED RESEARCH HIGHLIGHTING THE IMPORTANCE OF UNIFORM CELL SIZE IN MAINTAINING THE ARCHITECTURE OF EPITHELIAL SHEETS. ABNORMALLY SMALL EPITHELIAL CELLS CAN DISSOCIATE FROM EACH OTHER AND DISPERSE AMONG NORMAL CELLS. A SERIES OF EXPERIMENTS SHOWED THAT ABNORMAL SMALL-CELL DISPERSAL RESULTS FROM GEOMETRIC EFFECTS OF CELL SIZE VARIATION ON EPITHELIAL PACKING. THESE FINDINGS MAY FURTHER THE UNDERSTANDING OF HUMAN DISEASE PROGRESSION. THE STUDY WAS PUBLISHED ONLINE SEPTEMBER 5, 2019, IN DEVELOPMENTAL CELL. THE HAWLEY LAB DISCOVERED MORE DETAILS ABOUT HOW THE SYNAPTONEMAL COMPLEX IN MEIOSIS PERFORMS ITS JOB. THIS LARGE PROTEIN COMPLEX IS A CRITICAL PLAYER IN THE SEGREGATION OF CHROMOSOMES DURING MEIOSIS. EXPERIMENTS INDICATED THAT THE X CHROMOSOME OF THE FRUIT FLY IS SENSITIVE TO DEFECTS IN THE STRUCTURE OF THE SYNAPTONEMAL COMPLEX, WITH EFFECTS VARYING DEPENDING PARTLY ON THE STAGE OF MEIOSIS. THE RESEARCH MAY HELP FURTHER UNDERSTANDING OF THE CAUSES OF HUMAN MISCARRIAGE. THE WORK WAS PUBLISHED ONLINE SEPTEMBER 30, 2019, IN THE PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES. THE WASHBURN LAB UNCOVERED NEW DETAILS ABOUT SEVERAL PROTEINS IMPLICATED IN CANCER. THE RESEARCH FOCUSED ON THE SMAD4, A TRANSCRIPTION FACTOR THAT NORMALLY SUPPRESSES TUMOR GROWTH, AND A PROTEIN CALLED BRK THAT BINDS TO SMAD4 AND LEADS TO ITS BREAKDOWN. THEIR WORK EXAMINED THE PROTEINS IN HUMAN CELL LINES INCLUDING BREAST CELL CANCER TYPES AND SUGGESTED THAT TREATMENTS TARGETING BRK, WHICH IS PRESENT IN MORE THAN 85 PERCENT OF BREAST CANCER TUMORS, COULD HELP REDUCE OR STOP TUMOR GROWTH. THE STUDY WAS PUBLISHED ONLINE OCTOBER 23, 2019, IN SCIENCE ADVANCES. COMPREHENSIVE LISTS OF 2019 ORIGINAL RESEARCH PAPERS, REVIEWS, COMMENTARIES, CHAPTERS, AND BOOKS ORIGINAL RESEARCH PAPERS
1. EFFICIENT DEPLETION OF RIBOSOMAL RNA FOR SEQUENCING IN	PLANARIANS. KIM IV,ROSS EJ, DIETRICH S, DORING K, SNCHEZ ALVARADO A, KUHN CD. BMC GENOMICS.2019;20:909. DOI: 10.1186/S12864-019-6292-Y. 2. BRK PHOSPHORYLATES SMAD4 FOR PROTEASOMAL DEGRADATION AND INHIBITS TUMOR SUPPRESSOR FRK TO CONTROL SNAIL, SLUG AND METASTATIC POTENTIAL. MIAH S, BANKS CAS,OGUNBOLUDE Y, BAGU ET, BERG JM, SARAF A, TETTEY TT, HATTEM G, DAYEBGADOH G, KEMPF CG, SARDIU M, NAPPER S, FLORENS L, LUKONG KE, WASHBURN MP. SCI ADV.2019;5:EAAW3113. DOI: 3110.1126/SCIADV.AAW3113. 3. PLANARIANS RECRUIT PIRNAS FOR MRNA TURNOVER IN ADULT STEM CELLS. KIM IV, DUNCAN EM, ROSS EJ, GORBOVYTSKA V, NOWOTARSKI SH, ELLIOTT SA, SNCHEZ ALVARADO A, KUHN CD.GENES DEV. 2019;33:1575-1590. 4. AN ADULT BRAIN ATLAS REVEALS BROAD NEUROANATOMICAL CHANGES IN INDEPENDENTLY EVOLVED POPULATIONS OF MEXICAN CAVEFISH. LOOMIS C, PEUSS R, JAGGARD JB, WANG Y,MCKINNEY S, RAFTOPOULOS A, RAFTOPOULOS S, WHU D, GREEN MR, MCGAUGH SE, ROHNER NE, KEENE AC, DUBOUE ER. FRONT NEUROANAT. 2019;13:88. DOI: 10.3389/FNANA.2019.00088. 5. X CHROMOSOME AND AUTOSOMAL RECOMBINATION ARE DIFFERENTIALLY SENSITIVE TO DISRUPTIONS IN SC MAINTENANCE. BILLMYRE KK, CAHOON CK, HEENAN GM, WESLEY ER, YU Z,UNRUH JR, TAKEO S, HAWLEY RS. PROC NATL ACAD SCI U S A. 2019;116:21641-21650. 6. AN ATLAS OF TRANSCRIPTION FACTORS EXPRESSED IN MALE PUPAL TERMINALIA OF DROSOPHILA MELANOGASTER. VINCENT BJ, RICE GR, WONG GM, GLASSFORD WJ, DOWNS KI, SHASTAY JL, CHARLES-OBI K, NATARAJAN M, GOGOL M, ZEITLINGER J, REBEIZ M. G3(BETHESDA). 2019. DOI: 10.1534/G3.119.400788. 7. DEFINING THE EXPRESSION OF PIRNA AND TRANSPOSABLE ELEMENTS IN DROSOPHILA OVARIAN GERMLINE STEM CELLS AND SOMATIC SUPPORT CELLS. STORY B, MA X, ISHIHARA K, LI H, HALL K, PEAK A, ANOJA P, PARK J, HAUG J, BLANCHETTE M, XIE T. LIFE SCI ALLIANCE.2019;2:E201800211. DOI: 10.26508/LSA.XXX-XX-XXXX. 8. EVOLUTIONARY ORIGIN AND NOMENCLATURE OF VERTEBRATE WNT11-FAMILY GENES.POSTLETHWAIT JH, NAVAJAS ACEDO J, PIOTROWSKI T. ZEBRAFISH. 2019;16:469-476. 9. PERTURBED CRANIAL NEURAL CREST CELL DEVELOPMENT IN ASSOCIATION WITH REDUCED SONIC HEDGEHOG SIGNALING UNDERLIES THE PATHOGENESIS OF RETINOIC-ACID-INDUCED CLEFT PALATE. WANG Q, KUROSAKA H, KIKUCHI M, NAKAYA A, TRAINOR PA, YAMASHIRO T. DIS MODEL MECH. 2019;12. 10. EXPERIMENTAL EVOLUTION OF IMMUNOLOGICAL SPECIFICITY. FERRO K, PEUSS R, YANG W,ROSENSTIEL P, SCHULENBURG H, KURTZ J. [PUBLISHED AHEAD OF PRINT SEPTEMBER 23 2019].PNAS. 2019. 11. PROTRUSION MEMBRANE PEARLING EMERGES DURING THREE-DIMENSIONAL CELL DIVISION.CABALLERO D, MENDES PINTO I, RUBINSTEIN B, SAMITIER J. PHYS BIOL. 2019. 12. DNA-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (DNA-PKCS) CONTRIBUTES TO INCORPORATION OF HISTONE VARIANT H2A.Z INTO NUCLEOSOMES. WANG LY, HE YX, LI M,DING J, SUI Y, CONAWAY JW, CONAWAY RC, WANG F, JIN J, CAI Y. PROTEIN CELL. 2019;10:694-699. 13. IDENTIFICATION OF A NUCLEAR LOCALIZATION SIGNAL AND IMPORTIN BETA MEMBERS MEDIATING NUAK1 NUCLEAR IMPORT INHIBITED BY OXIDATIVE STRESS. PALMA M, RIFFO EN,SUGANUMA T, WASHBURN MP, WORKMAN JL, PINCHEIRA R, CASTRO AF. J CELL BIOCHEM.2019;120:16088-16107. 14. CELL-SIZE PLEOMORPHISM DRIVES ABERRANT CLONE DISPERSAL IN PROLIFERATING EPITHELIA. RAMANATHAN SP, KRAJNC M, GIBSON MC. DEV CELL. 2019;51:49-61 E44. 15. PCP AND WNT PATHWAY COMPONENTS ACT IN PARALLEL DURING ZEBRAFISH MECHANOSENSORY HAIR CELL ORIENTATION. NAVAJAS ACEDO J, VOAS MG, ALEXANDER R, WOOLLEY T, UNRUH JR, LI H, MOENS C, PIOTROWSKI T. NAT COMMUN. 2019;10:3993. DOI:3910.1038/S41467-41019-12005-Y. 16. BIOCHEMICAL REDUCTION OF THE TOPOLOGY OF THE DIVERSE WDR76 PROTEIN INTERACTOME.DAYEBGADOH G, SARDIU ME, FLORENS L, WASHBURN MP. J PROTEOME RES. 2019;18:3479-3491. 17. GENERATING TOPOLOGICAL PROTEIN INTERACTION SCORES AND DATA VISUALIZATION WITH TOPS. SARDIU M, FLORENS L, WASHBURN MP. [PUBLISHED AHEAD OF PRINT SEPTEMBER 3 2019]. METHODS. 2019. 18. CLUSTERMAP: COMPARE MULTIPLE SINGLE CELL RNA-SEQ DATASETS ACROSS DIFFERENT EXPERIMENTAL CONDITIONS. GAO X, HU D, GOGOL M, LI H. BIOINFORMATICS. 2019;35:3038-3045. 19. AN ATLAS OF ANTERIOR HOX GENE EXPRESSION IN THE EMBRYONIC SEA LAMPREY HEAD: HOXCODE EVOLUTION IN VERTEBRATES. PARKER HJ, BRONNER ME, KRUMLAUF R. DEV BIOL.2019;453:19-33. 20. STABLE TRANSGENESIS IN ASTYANAX MEXICANUS USING THE TOL2 TRANSPOSASE SYSTEM.STAHL BA, PEUSS R, MCDOLE B, KENZIOR A, JAGGARD JB, GAUDENZ K, KRISHNAN J, MCGAUGH SE, DUBOUE ER, KEENE AC, ROHNER N. DEV DYN. 2019;248:679-687. 21. THE E3 UBIQUITIN LIGASE SPOP CONTROLS RESOLUTION OF SYSTEMIC INFLAMMATION BY TRIGGERING MYD88 DEGRADATION. GUILLAMOT M, OUAZIA D, DOLGALEV I, YEUNG ST,KOURTIS N, DAI Y, CORRIGAN K, ZEA-REDONDO L, SARAF A, FLORENS L, WASHBURN MP,TIKHONOVA AN, MALUMBRES M, GONG Y, TSIRIGOS A, PARK C, BARBIERI C, KHANNA KM,BUSINO L, AIFANTIS I. NAT IMMUNOL. 2019;20:1196-1207. 22. A CONSERVED REGULATORY PROGRAM INITIATES LATERAL PLATE MESODERM EMERGENCE ACROSS CHORDATES. PRUMMEL KD, HESS C, NIEUWENHUIZE S, PARKER HJ, ROGERS KW,KOZMIKOVA I, RACIOPPI C, C. BE, CZARKWIANI A, KNAPP D, BURGER S, CHIAVACCI E, SHAH G,BURGER A, HUISKEN J, YUN M, CHRISTIAEN L, KOZMIK Z, CHRISTIAEN L, MULLER P, BRONNER M,KRUMLAUF R, MOSIMANN C. NAT COMMUN. 2019;10:E3857. DOI: 3810.1038/S41467-41019-11561-41467. 23. MEASURING SIMILARITY BETWEEN GENE INTERACTION PROFILES. BARIDO-SOTTANI J,CHAPMAN SD, KOSMAN E, MUSHEGIAN AR. BMC BIOINFORMATICS. 2019;20:435. DOI:410.1186/S12859-12019-13024-X. 24. COMPARISON OF BLEACHING PROTOCOLS UTILIZING HEMATOXYLIN AND EOSIN STAIN ANDIMMUNOHISTOCHEMICAL PROLIFERATION MARKER MCM3 IN PIGMENTED MELANOMAS. JORDAN T, WILLIAMS D, CRISWELL S, WANG Y. [PUBLISHED AHEAD OF PRINT AUGUST 17 2019].J HISTOTECHNOL. 2019:1-6. 25. ALKALINE PHOSPHATASE-BASED CHROMOGENIC AND FLUORESCENCE DETECTION METHOD FOR BASESCOPE IN SITU HYBRIDIZATION. WANG Y, XU W, MADDERA L, TSUCHIYA D, THOMAS N, YU CR, PARMELY T. [PUBLISHED AUGUST 17 2019]. J HISTOTECHNOL. 2019:1-9. 26. WNT AND TGF-? COORDINATE GROWTH AND PATTERNING TO REGULATE SIZE-DEPENDENT BEHAVIOR. ARNOLD CP, BENHAM-PYLE BW, LANGE JJ, WOOD CJ, SNCHEZ ALVARADO A.NATURE. 2019;572:655-659. 27. DETECTING AND CHARACTERIZING PROTEIN SELF-ASSEMBLY IN VIVO BY FLOW CYTOMETRY.VENKATESAN S, KANDOLA TS, RODRIGUEZ-GAMA A, BOX A, HALFMANN R. J VIS EXP.2019;149:E59577. DOI: 59510.53791/59577. 28. FILLING IN THE PHYLOGENETIC GAPS: INDUCTION, MIGRATION AND DIFFERENTIATION OF NEURAL CREST CELLS IN A SQUAMATE REPTILE, THE VEILED CHAMELEON (CHAMAELEOCALYPTRATUS). DIAZ RE, JR., SHYLO NA, ROELLIG D, BRONNER M, TRAINOR PA. DEV DYN.2019;248:709-727. 29. THE TRANSCRIPTOME OF THE VEILED CHAMELEON (CHAMAELEO CALYPTRATUS): A RESOURCE FOR STUDYING THE EVOLUTION AND DEVELOPMENT OF VERTEBRATES. PINTO BJ, CARD DC, CASTOE TA, DIAZ RE, JR., NIELSEN SV, TRAINOR PA, GAMBLE T. DEV DYN. 2019;248:702-708. 30. RUNX PROTEINS DESENSITIZE MULTIPLE MYELOMA TO LENALIDOMIDE VIA PROTECTING IKZFS FROM DEGRADATION. ZHOU N, GUTIERREZ-UZQUIZA A, ZHENG XY, CHANG R, VOGL DT,GARFALL AL, BERNABEI L, SARAF A, FLORENS L, WASHBURN MP, ILLENDULA A, BUSHWELLER JH,BUSINO L. LEUKEMIA. 2019;33:2006-2021. 31. ATAXIN-7 AND NON-STOP COORDINATE SCAR PROTEIN LEVELS, SUBCELLULAR LOCALIZATION,AND ACTIN CYTOSKELETON ORGANIZATION. CLOUD V, THAPA A, MORALES-SOSA P, MILLER T,MILLER SA, HOLSAPPLE D, GERHART P, MOMTAHAN E, JACK JL, LEIVA E, RAPP SR, SHELTON LG,PIERCE RA, MARTIN-BROWN S, FLORENS L, WASHBURN MP, MOHAN RD. ELIFE. 2019;8. DOI:10.7554/ELIFE.49677. 32. STRUCTURES OF AUTOINHIBITED AND POLYMERIZED FORMS OF CARD9 REVEAL MECHANISMS OF CARD9 AND CARD11 ACTIVATION. HOLLIDAY MJ, WITT A, RODRIGUEZ GAMA A, WALTERS BT,ARTHUR CP, HALFMANN R, ROHOU A, DUEBER EC, FAIRBROTHER WJ. NAT COMMUN.2019;10:3070. DOI: 10.1038/S41467-019-10953-Z. 33. COMPREHENSIVE SINGLE-CELL TRANSCRIPTOME LINEAGES OF A PROTO-VERTEBRATE. CAO C,LEMAIRE LA, WANG W, YOON PH, CHOI YA, PARSONS LR, MATESE JC, WANG W, LEVINE M,CHEN K. NATURE. 2019;571:349-354.
34. AMYLOID-LIKE ASSEMBLY ACTIVATES A PHOSPHATASE IN THE DEVELOPING	DROSOPHILA EMBRYO. NIL Z, MILLAN RH, GERBICH T, LEAL P, YU Z, SARAF A, SARDIU M, LANGE JJ, YI K, UNRUH J, SLAUGHTER B, SI K. CELL. 2019;178:1403-1420 E1421. 35. SUPER-RESOLUTION MICROSCOPY REVEALS LINKAGES BETWEEN RIBOSOMAL DNA ON HETEROLOGOUS CHROMOSOMES. POTAPOVA TA, UNRUH JR, YU Z, RANCATI G, LI H, STAMPFER MR, GERTON JL. J CELL BIOL. 2019;218:2492-2513. 36. SIGNATURES OF DIVERGENCE, INVASIVENESS AND TERRESTRALIZATION REVEALED BY FOUR APPLE SNAIL GENOMES. SUN J, MU H, IP JCH, LI R, XU T, ACCORSI A, SNCHEZ ALVARADO A, ROSS E, LAN Y, SUN Y, CASTRO-VAZQUEZ A, VEGA IA, HERAS H, ITUARTE S, VAN BOCXLAER B, HAYES KA, COWIE RH, ZHAO Z, ZHANG Y, QIAN PY, QIU JW. MOL BIOL EVOL. 2019;36:1507-1520. 37. P53 AND B-CATENIN EXPRESSION PREDICT POORER PROGNOSIS IN PATIENTS WITH ANAPLASTIC LARGE-CELL LYMPHOMA. RICHARDSON AI, YIN CC, CUI W, LI N, MEDEIROS LJ, LI L, ZHANG D. CLIN LYMPHOMA MYELOMA LEUK. 2019;19:E385-E392. DOI: 310.1016/J.CLML.2019.1003.1030. 38. THE STOICHIOMETRY OF THE OUTER KINETOCHORE IS MODULATED BY MICROTUBULE-PROXIMAL REGULATORY FACTORS. DHATCHINAMOORTHY K, UNRUH JR, LANGE JJ, LEVY M, SLAUGHTER BD, GERTON JL. J CELL BIOL. 2019;218:2124-2135. 39. THE EXOCYST FUNCTIONS IN NICHE CELLS TO PROMOTE GERMLINE STEM CELL DIFFERENTIATION BY DIRECTLY CONTROLLING EGFR MEMBRANE TRAFFICKING. MAO Y, TU R, HUANG Y, MAO D, YANG Z, LAU PK, WANG J, NI J, GUO Y, XIE T. DEVELOPMENT. 2019;146:DEV174615 DOI: 174610.171242/DEV.174615. 40. A ROLE FOR FACT IN RNA POLYMERASE II PROMOTER-PROXIMAL PAUSING. TETTEY TT, GAO X, SHAO W, STORY BA, CHITSAZAN AD, GLASER RL, SEIDEL CW, CONAWAY RC, ZEITLINGER J, BLANCHETTE M, CONAWAY JW. CELL REP. 2019;27:3770-3779 E7. 41. JUNCTIONAL TUMOR SUPPRESSORS INTERACT WITH 14-3-3 PROTEINS TO CONTROL PLANAR SPINDLE ALIGNMENT. NAKAJIMA YI, LEE ZT, MCKINNEY SA, SWANSON SK, FLORENS L, GIBSON MC. J CELL BIOL. 2019;218:1824-1838. 42. STRUCTURE AND FUNCTION OF SPC42 COILED-COILS IN YEAST CENTROSOME ASSEMBLY AND DUPLICATION. DRENNAN AC, KRISHNA S, SEEGER MA, ANDREAS MP, GARDNER JM, SETHER EKR, JASPERSEN SL, RAYMENT I. MOL BIOL CELL. 2019;30:1505-1522. 43. KILLER MEIOTIC DRIVE AND DYNAMIC EVOLUTION OF THE WTF GENE FAMILY. EICKBUSH MT, YOUNG JM, ZANDERS SE. MOL BIOL EVOL. 2019;36:1201-1214. 44. GAMETE COLLECTION AND IN VITRO FERTILIZATION OF ASTYANAX MEXICANUS. PEUSS R, ZAKIBE Z, KRISHNAN J, MERRYMAN MS, BAUMANN DP, ROHNER N. J VIS EXP. 2019. DOI: 10.3791/59334. 45. DOWNREGULATION OF FGF SIGNALING BY SPRY4 OVEREXPRESSION LEADS TO SHAPE IMPAIRMENT, ENAMEL IRREGULARITIES, AND DELAYED SIGNALING CENTER FORMATION IN THE MOUSE MOLAR. MARANGONI P, CHARLES C, AHN Y, SEIDEL K, JHEON A, GANSS B, KRUMLAUF R, VIRIOT L, KLEIN OD. JBMR PLUS. 2019;3:E10205. DOI: 10210.11002/JBM10204.10205. 46. THE E3 UBIQUITIN LIGASE SINA REGULATES THE ASSEMBLY AND DISASSEMBLY OF THE SYNAPTONEMAL COMPLEX IN DROSOPHILA FEMALES. HUGHES SE, HEMENWAY E, GUO F, YI K, YU Z, HAWLEY RS. PLOS GENET. 2019;15:E1008161. DOI: 10.1371/JOURNAL.PGEN.1008161. 47. ARTIFICIAL RNA POLYMERASE II ELONGATION COMPLEXES FOR DISSECTING CO-TRANSCRIPTIONAL RNA PROCESSING EVENTS. NOE GONZALEZ M, CONAWAY JW, CONAWAY RC. J VIS EXP. 2019;147: DOI: 10.3791/59497. 48. HYPO-OSMOTIC-LIKE STRESS UNDERLIES GENERAL CELLULAR DEFECTS OF ANEUPLOIDY. TSAI HJ, NELLIAT AR, CHOUDHURY MI, KUCHARAVY A, BRADFORD WD, COOK ME, KIM J, MAIR DB, SUN SX, SCHATZ MC, LI R. NATURE. 2019;570:117-121. 49. YEAST CENTROSOME COMPONENTS FORM A NONCANONICAL LINC COMPLEX AT THE NUCLEAR ENVELOPE INSERTION SITE. CHEN J, GARDNER JM, YU Z, SMITH SE, MCKINNEY S, SLAUGHTER BD, UNRUH JR, JASPERSEN SL. J CELL BIOL. 2019;218:1478-1490. 50. DOPAMINE RECEPTOR ANTAGONISTS AS POTENTIAL THERAPEUTIC AGENTS FOR ADPKD. PAUL P, RAMACHANDRAN S, XIA S, UNRUH JR, CONKRIGHT-FINCHAM J, LI R. PLOS ONE. 2019;14:E0216220. DOI: 10.1371/JOURNAL.PONE.0216220. 51. REPORTER-CHIP-NEXUS REVEALS STRONG CONTRIBUTION OF THE DROSOPHILA INITIATOR SEQUENCE TO RNA POLYMERASE PAUSING. SHAO W, ALCANTARA SG, ZEITLINGER J. ELIFE. 2019;8:E41461. DOI: 41410.47554/ELIFE.41461. 52. TRANSLATION AFFECTS MRNA STABILITY IN A CODON-DEPENDENT MANNER IN HUMAN CELLS. WU Q, MEDINA SG, KUSHAWAH G, DEVORE ML, CASTELLANO LA, HAND JM, WRIGHT M, BAZZINI AA. ELIFE. 2019;8:E45396. DOI: 45310.47554/ELIFE.45396. 53. SET1-CATALYZED H3K4 TRIMETHYLATION ANTAGONIZES THE HIR/ASF1/RTT106 REPRESSOR COMPLEX TO PROMOTE HISTONE GENE EXPRESSION AND CHRONOLOGICAL LIFE SPAN. MEI Q, XU C, GOGOL M, TANG J, CHEN W, YU X, WORKMAN JL, LI S. NUCLEIC ACIDS RES. 2019;47:3434-3449. 54. EVALUATING CHROMATOGRAPHIC APPROACHES FOR THE QUANTITATIVE ANALYSIS OF A HUMAN PROTEOME ON ORBITRAP-BASED MASS SPECTROMETRY SYSTEMS. ZHANG Y, WEN Z, WASHBURN MP, FLORENS L. J PROTEOME RES. 2019;18:1857-1869. 55. DISTRIBUTION OF PROTEINS AT THE INNER NUCLEAR MEMBRANE IS REGULATED BY THE ASI1 E3 LIGASE IN SACCHAROMYCES CEREVISIAE. SMOYER CJ, SMITH SE, GARDNER JM, MCCROSKEY S, UNRUH JR, JASPERSEN SL. GENETICS. 2019;211:1269-1282. 56. DYRK1A REGULATES THE RECRUITMENT OF 53BP1 TO THE SITES OF DNA DAMAGE IN PART THROUGH INTERACTION WITH RNF169. MENON VR, ANANTHAPADMANABHAN V, SWANSON S, SAINI S, SESAY F, YAKOVLEV V, FLORENS L, DECAPRIO JA, WASHBURN MP, DOZMOROV M, LITOVCHICK L. CELL CYCLE. 2019;18:531-551. 57. A HOX-TALE REGULATORY CIRCUIT FOR NEURAL CREST PATTERNING IS CONSERVED ACROSS VERTEBRATES. PARKER HJ, DE KUMAR B, GREEN SA, PRUMMEL KD, HESS C, KAUFMAN CK, MOSIMANN C, WIEDEMANN LM, BRONNER ME, KRUMLAUF R. NAT COMMUN. 2019;10:1189. DOI: 1110.1038/S41467-41019-09197-41468. 58. TOPOLOGICAL SCORING OF PROTEIN INTERACTION NETWORKS. SARDIU ME, GILMORE JM, GROPPE BD, DUTTA A, FLORENS L, WASHBURN MP. NAT COMMUN. 2019;10:1118. DOI: 1110.1038/S41467-41019-09123-Y. 59. IMAGING-BASED ASSAYS FOR INVESTIGATING FUNCTIONS OF THE RNA POLYMERASE II ELONGATION FACTOR ELONGIN AND THE ELONGIN UBIQUITIN LIGASE. WEEMS JC, UNRUH JR, SLAUGHTER BD, CONAWAY RC, CONAWAY JW. METHODS. 2019;159-160:157-164. 60. CHARACTERIZATION OF A METAZOAN ADA ACETYLTRANSFERASE COMPLEX. SOFFERS JHM, LI X, SARAF A, SEIDEL CW, FLORENS L, WASHBURN MP, ABMAYR SM, WORKMAN JL. NUCLEIC ACIDS RES. 2019;47:3383-3394. 61. A CHEMOPROTEOMIC PORTRAIT OF THE ONCOMETABOLITE FUMARATE. KULKARNI RA, BAK DW, WEI D, BERGHOLTZ SE, BRINEY CA, SHRIMP JH, ALPSOY A, THORPE AL, BAVARI AE, CROOKS DR, LEVY M, FLORENS L, WASHBURN MP, FRIZZELL N, DYKHUIZEN EC, WEERAPANA E, LINEHAN WM, MEIER JL. NAT CHEM BIOL. 2019;15:391-400 62. HOST VESICLE FUSION PROTEIN VAPB IS REQUIRED FOR THE NUCLEAR EGRESS STAGE OF HERPES SIMPLEX VIRUS TYPE-1 (HSV-1) REPLICATION. SAIZ-ROS N, CZAPIEWSKI R, EPIFANO I, STEVENSON A, SWANSON SK, DIXON CR, ZAMORA DB, MCELWEE M, VIJAYAKRISHNAN S, RICHARDSON CA, DONG L, KELLY DA, PYTOWSKI L, GOLDBERG MW, FLORENS L, GRAHAM SV, SCHIRMER EC. CELLS. 2019;8 E120. DOI: 110.3390/CELLS8020120. 63. TOWARDS THE MOLECULAR DECIPHERING OF POMACEA CANALICULATA IMMUNITY: FIRST PROTEOMIC ANALYSIS OF CIRCULATING HEMOCYTES. BORALDI F, LOFARO FD, ACCORSI A, ROSS E, MALAGOLI D. PROTEOMICS. 2019;19:E1800314. DOI: 1800310.1801002/PMIC.XXX-XX-XXXX. 64. DEFINING GENE NETWORKS CONTROLLING THE MAINTENANCE AND FUNCTION OF THE DIFFERENTIATION NICHE BY AN IN VIVO SYSTEMATIC RNAI SCREEN. GAO Y, MAO Y, XU RG, ZHU R, ZHANG M, SUN J, SHEN D, PENG P, XIE T, NI JQ. J GENET GENOME. 2019;46:19-30. 65. SCRNA-SEQ REVEALS DISTINCT STEM CELL POPULATIONS THAT DRIVE HAIR CELL REGENERATION AFTER LOSS OF FGF AND NOTCH SIGNALING. LUSH ME, DIAZ DC, KOENECKE N, BAEK S, BOLDT H, ST PETER MK, GAITAN-ESCUDERO T, ROMERO-CARVAJAL A, BUSCH-NENTWICH EM, PERERA AG, HALL KE, PEAK A, HAUG JS, PIOTROWSKI T. ELIFE. 2019;8:E44431. DOI: 44410.47554/ELIFE.44431. 66. N-CADHERIN-EXPRESSING BONE AND MARROW STROMAL PROGENITOR CELLS MAINTAIN RESERVE HEMATOPOIETIC STEM CELLS. ZHAO M, TAO F, VENKATRAMAN A, LI Z, SMITH SE, UNRUH J, CHEN S, WARD C, QIAN P, PERRY JM, MARSHALL H, WANG J, HE XC, LI L. CELL REP. 2019;26:652-669 E656. 67. THE DROSOPHILA DBF4 ORTHOLOG CHIFFON FORMS A COMPLEX WITH GCN5 THAT IS NECESSARY FOR HISTONE ACETYLATION AND VIABILITY. TORRES-ZELADA EF, STEPHENSON RE, ALPSOY A, ANDERSON BD, SWANSON SK, FLORENS L, DYKHUIZEN EC, WASHBURN MP, WEAKE VM. J CELL SCI. 2019;132:JCS.214072. 68. ELECTROPORATION OF SHORT HAIRPIN RNAS FOR RAPID AND EFFICIENT GENE KNOCKDOWN IN THE STARLET SEA ANEMONE, NEMATOSTELLA VECTENSIS. KARABULUT A, HE S, CHEN CY, MCKINNEY SA, GIBSON MC. DEV BIOL. 2019;448:7-15. 69. OOCYTE-SPECIFIC DELETION OF HDAC8 IN MICE REVEALS STAGE-SPECIFIC EFFECTS ON FERTILITY. SINGH VP, YUEH WT, GERTON JL, DUNCAN FE. REPRODUCTION. 2019;157:305-316. 70. NARYA, A RING FINGER DOMAIN-CONTAINING PROTEIN, IS REQUIRED FOR BOTH MEIOTIC DNA DOUBLE-STRAND BREAK FORMATION AND CROSSOVER MATURATION IN DROSOPHILA MELANOGASTER. LAKE CM, NIELSEN RJ, BONNER AM, ECHE S, WHITE-BROWN S, MCKIM KS, HAWLEY RS. PLOS GENET. 2019;15:E1007886. DOI:1007810.1001371/JOURNAL.PGEN.1007886.
71. SHH PLAYS AN INHIBITORY ROLE IN CUSP PATTERNING BY REGULATION OF	SOSTDC1. KIM J, AHN Y, ADASOORIYA D, WOO EJ, KIM HJ, HU KS, KRUMLAUF R, CHO SW. J DENT RES. 2019;98:98-106. 72. FUNCTIONAL CONSEQUENCES OF THE EVOLUTION OF MATRIMONY, A MEIOSIS-SPECIFIC INHIBITOR OF POLO KINASE. BONNER AM, HAWLEY RS. MOL BIOL EVOL. 2019;36:69-83. 73. GLYCOLYSIS REGULATES GENE EXPRESSION BY PROMOTING THE CROSSTALK BETWEEN H3K4 TRIMETHYLATION AND H3K14 ACETYLATION IN SACCHAROMYCES CERVISIAE. WU Y, ZHANG S, GONG X, YU Q, ZHANG Y, LUO M, ZHANG X, WORMAN JL, YU X, LI S. J GENET GENOMICS. 2019;46:561-574. 74. UNIDIRECTIONAL PROPULSION OF PLANAR MAGNETIC NANOMACHINES. COHEN K-J, RUBINSTEIN BY, KENNETH O, LESHANSKY AM. PHYS REV APPLIED. 2019;12:014025:1-10. REVIEWS, COMMENTARIES, CHAPTERS, AND BOOKS 1. CONTINUING THE ADVANCEMENT OF JOURNAL OF HISTOTECHNOLOGY - ONE ISSUE AT A TIME. WANG Y. J HISTOTECHNOL. 2019;42:165-166. 2. EXOGENOUS PYRUVATE REPRESSES HISTONE GENE EXPRESSION AND INHIBITS CANCER CELL PROLIFERATION VIA THE NAMPT-NAD+-SIRT1 PATHWAY. MA R, WU Y, ZHAI Y, HU B, MA W, YANG W, YU Q, CHEN Z, WORKMAN JL, YU X, LI S. NUCLEIC ACIDS RES. 2019;47:11132-11150. 3. THE JOY OF BALANCERS. MILLER DE, COOK KR, HAWLEY RS. PLOS GENET. 2019;15:E1008421. DOI: 1008410.1001371/JOURNAL.PGEN.1008421. 4. REBOOTING THE EPIGENOME: ERASURE OF PARENTAL HISTONE MARKS FOR ESTABLISHING THE REGULATORY LANDSCAPE IN ZYGOTES. BHATTACHARYA S, WORKMAN JL. [PUBLISHED AHEAD OF PRINT OCTOBER 23 2019]. BIOCHEMISTRY. 2019. 5. BEYOND BASIC AT THE STOWERS INSTITUTE FOR MEDICAL RESEARCH. BLAND K, ORR AA. MO MED. 2019;116:457-460. 6. AN INTERDISCIPLINARY APPROACH TO INVESTIGATE COLLECTIVE CELL MIGRATION IN NEURAL CREST. GINIUNAITE R, MCLENNAN R, MCKINNEY MC, BAKER RE, KULESA PM, MAINI PK. [PUBLISHED AHEAD OF PRINT OCTOBER 18 2019]. DEV DYN. 2019. 7. PURIFICATION AND ENZYMATIC ASSAY OF CLASS I HISTONE DEACETYLASE ENZYMES. ADAMS MK, BANKS CAS, MIAH S, KILLER M, WASHBURN MP. METHODS ENZYMOL. 2019;626:23-40. 8. COMPARING SENSORY ORGANS TO DEFINE THE PATH FOR HAIR CELL REGENERATION. DENANS N, BAEK S, PIOTROWSKI T. ANNU REV CELL DEV BIOL. 2019;35:568-589. 9. NSL COMPLEX ACETYLATES LAMIN A/C. POPOVA VV, WORKMAN JL. NAT CELL BIOL. 2019;21:1177-1178. 10. PATROLLING THE NUCLEUS: INNER NUCLEAR MEMBRANE-ASSOCIATED DEGRADATION. SMOYER CJ, JASPERSEN SL. CURR GENET. 2019;65:1099-1106. 11. THE HUNT FOR RNA POLYMERASE II ELONGATION FACTORS: A HISTORICAL PERSPECTIVE. CONAWAY RC, CONAWAY JW. NAT STRUCT MOL BIOL. 2019;26:771-776. 12. REGULATION OF GENOMIC OUTPUT AND (PLURI)POTENCY IN REGENERATION. DUNCAN EM, SNCHEZ ALVARADO A. ANNU REV GENET. 2019;53:16.1-16.20. 13. CNIDOFEST 2018: THE FUTURE IS BRIGHT FOR CNIDARIAN RESEARCH. HE S, GRASIS JA, NICOTRA ML, JULIANO CE, SCHNITZLER CE. EVODEVO. 2019;10:20. DOI: 10.1186/S13227-13019-10134-13225. 14. HISTONE LYSINE DE-BETA-HYDROXYBUTYRYLATION BY SIRT3. ABMAYR SM, WORKMAN JL. CELL RES. 2019;29:694-695. 15. GENE CONVERSION GENERATES EVOLUTIONARY NOVELTY THAT FUELS GENETIC CONFLICTS. DAUGHERTY MD, ZANDERS SE. V.CURR OPIN GENET DE 2019;58:49-54. 16. A FAMILY OF KILLERS. DE CARVALHO M, ZANDERS SE. ELIFE. 2019;8:E46454. DOI: 46410.47554/ELIFE.46454. 17. WHEN MOTHERS LEAVE THEIR MARK. BARAJAS-AZPELETA R, SI K. ELIFE. 2019;8:E48899. DOI:48810.47554/ELIFE.48899. 18. HEMATOPOIETIC STEM CELLS: SELF-RENEWAL AND EXPANSION. LI Z, HE XC, LI L. CURR OPIN HEMATOL. 2019;26:258-265. 19. FERTILITY COSTS OF MEIOTIC DRIVERS. ZANDERS SE, UNCKLESS RL. CURR BIOL. 2019;29:R512-R520. 20. CORNELIA DE LANGE SYNDROME, RELATED DISORDERS, AND THE COHESIN COMPLEX: ABSTRACTS FROM THE 8TH BIENNIAL SCIENTIFIC AND EDUCATIONAL SYMPOSIUM 2018. KLINE AD, KRANTZ ID, BANDO M, SHIRAHIGE K, CHEA S, SAKATA T, RAO S, DORSETT D, SINGH VP, GERTON JL, HORSFIELD JA, CALOF AL, KATZ O, GRADOS M, RAIBLE S, BARANANO K, LYON G, MUSIO A, CARRICO CS, CLEMENS DK, CAUDILL P, MASSA V, MCGILL BE, DOMMESTRUP A, O'CONNOR J, HAALAND RE. AM J MED GENET A. 2019;179:1030-1090. 21. HOX GENES: DOWNSTREAM "EFFECTORS" OF RETINOIC ACID SIGNALING IN VERTEBRATE EMBRYOGENESIS. NOLTE C, DE KUMAR B, KRUMLAUF R. GENESIS. 2019:E23306. DOI:10.1002/DVG.23306. 22. NICHE CELLS REWIRED TO MAINTAIN HSCS EX VIVO. VENKATRAMAN A, LI L. NAT CELL BIOL. 2019;21:540-541. 23. COMMENTARY ON "REGENERATION, DUPLICATION AND TRANSDETERMINATION IN FRAGMENTS OF THE LEG DISC OF DROSOPHILA MELANOGASTER": SCHUBIGER, G. (1971). DEV BIOL. 2019;449:63-82.. GIBSON MC. DEV BIOL. 2019;449:63-82. 24. IN OVO ELECTROPORATION OF PLASMID DNA AND MORPHOLINOS INTO SPECIFIC TISSUES DURING EARLY EMBRYOGENESIS. MCLENNAN R, KULESA PM. METHODS MOL BIOL.2019;1976:71-82. 25. MOUSE EMBRYO CULTURE FOR THE STUDY OF NEURAL CREST CELLS. MUNOZ WA, TRAINOR PA. METHODS MOL BIOL: MEIOSIS. 2019;1976:107-119. 26. OBSERVATION OF TWO SEPARATE BIPOLAR SPINDLES IN THE HUMAN ZYGOTE. XU, X., LI L, ZHANG C, MENG L. J ASSIST REPROD GENET. 2019;36:601-602. CORRECTION: J ASSIST REPROD GENET. 2019 JUL 31. PII: 10.1007/S10815-019-01539-1. DOI: 10.1007/S10815-019-01539-1. 27. SWEET FISH: FISH MODELS FOR THE STUDY OF HYPERGLYCEMIA AND DIABETES. KRISHNAN J, ROHNER N. J DIABETES. 2019;11:193-203. 28. RIBOSOMAL DNA INSTABILITY AND GENOME ADAPTABILITY. SALIM D, GERTON JL. CHROMOSOME RES. 2019;27:73-87. 29. RIBOSOMAL DNA AND THE NUCLEOLUS IN THE CONTEXT OF GENOME ORGANIZATION. POTAPOVA TA, GERTON JL. CHROMOSOME RES. 2019;27:109-127. 30. THE SOCIETY FOR CRANIOFACIAL GENETICS AND DEVELOPMENTAL BIOLOGY 41ST ANNUAL MEETING. TANEYHILL LA, MOODY SA, COX T, KLEIN OD, MARCUCIO R, SCHNEIDER RA, TRAINOR PA. AM J MED GENET A. 2019;179:864-869. 31. MANIPULATION OF DEVELOPMENTAL FUNCTION IN TURTLES WITH NOTES ON ALLIGATORS. MOUSTAKAS-VERHO JE, MCLENNAN R, SPENGLER J, KULESA PM, CEBRA-THOMAS JA. METHODS MOL BIOL. 2019;1920:247-263. AUTHOR'S CORRECTION: METHODS MOL BIOL. 2019;1920:C1. 32. AN INTEGRATIVE VIEW OF LEPIDOSAUR CRANIAL ANATOMY, DEVELOPMENT AND DIVERSIFICATION. DIAZ JR. RE, TRAINOR PA. IN: ZIERMANN, D JR., AND DIOGO, EDS. HEADS, JAWS AND MUSCLES ANATOMICAL, FUNCTIONAL AND DEVELOPMENTAL DIVERSITY IN CHORDATE EVOLUTION, SPRINGER; 2019:207-227. 33. RIBOSOMAL DNA-CONNECTING RIBOSOME BIOGENESIS AND CHROMOSOME BIOLOGY. POROKHOVNIK L, GERTON JL. CHROMOSOME RES. 2019;27:1-3. 34. RECENT ADVANCES IN UNDERSTANDING INTESTINAL STEM CELL REGULATION. HU D, YAN H, HE XC, LI L. F1000RES. 2019;8:F1000 FACULTY REV-72. PUBLISHED 2019 JAN 18. DOI:10.12688/F1000RESEARCH.16793.1 COMPETITIVE RESEARCH GRANT FUNDING & RESEARCH AWARDS & DISTINCTIONS THE ABILITY OF SIMR SCIENTISTS TO RECEIVE COMPETITIVELY AWARDED RESEARCH FUNDING ATTESTS TO THE HIGH LEVEL OF RESEARCH PRODUCTIVITY PRESENT AT SIMR. DURING 2019, SIMR SCIENTISTS WORKED WITH THE SUPPORT OF 31 GRANTS AND FELLOWSHIPS FROM THE NATIONAL INSTITUTES OF HEALTH, TWO GRANTS FROM THE NATIONAL SCIENCE FOUNDATION, TWO GRANTS FROM THE MARCH OF DIMES, ONE GRANT FROM THE GREATER KANSAS CITY COMMUNITY FOUNDATION, ONE GRANT FROM THE HEARING HEALTH FOUNDATION, ONE FELLOWSHIP FROM THE JANE COFFIN CHILDS MEMORIAL FUND, ONE AWARD FROM THE SEARLE SCHOLARS PROGRAM, ONE AWARD FROM THE PEW CHARITABLE TRUSTS, ONE AWARD FROM THE UNIVERSITY OF KANSAS ENDOWMENT ASSOCIATION, ONE GRANT FROM THE EDWARD MALLINCKRODT JR. FOUNDATION, ONE GRANT FROM THE JUVENILE DIABETES RESEARCH FOUNDATION, ONE GRANT FROM THE UNIVERSITY OF KANSAS ALZHEIMER'S DISEASE CENTER, ONE GRANT FROM THE UNIVERSITY OF KANSAS CANCER CENTER, AND ONE INVESTIGATOR AWARD FROM THE HOWARD HUGHES MEDICAL INSTITUTE. SUPPORT FROM NEW AND CONTINUING AWARDS TO SIMR TOTALED MORE THAN $6.2 MILLION IN 2019 TO SUPPLEMENT INCOME FROM ITS ENDOWMENTS. TESTIFYING TO THE HIGH LEVEL OF ACHIEVEMENT TAKING PLACE AT SIMR ARE THE AWARDS AND HONORS SIMR MEMBERS RECEIVED IN 2019: 1. NICOLAS ROHNER, PHD, RECEIVED A TWO-YEAR GRANT FROM THE JUVENILE DIABETES RESEARCH FOUNDATION 2. TING XIE, PHD, WAS AWARDED A FIVE-YEAR GRANT FROM THE NIH EUNICE SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT 3. LINHENG LI, PHD, RECEIVED A FIVE-YEAR GRANT FROM THE NIH NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES 4. ARIEL BAZZINI, PHD, RECEIVED A TWO-YEAR PEW INNOVATION FUND AWARD ALONG WITH COLLABORATOR DIEGO ALVAREZ, PHD, FROM THE NATIONAL UNIVERSITY OF SAN MARTIN, ARGENTINA 5. RANDAL HALFMANN, PHD, RECEIVED A FOUR-YEAR NIH GRANT FROM THE NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES 6. ERIC HILL, PHD, A POSTDOCTORAL RESEARCHER IN THE GIBSON LAB, WAS AWARDED A TWOYEAR NIH FELLOWSHIP FROM THE NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES 7. CASSANDRA KEMPF, A PREDOCTORAL RESEARCHER OF THE GRADUATE SCHOOL OF THE STOWERS INSTITUTE, RECEIVED A THREE-YEAR FELLOWSHIP FROM THE NIH NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES 8. STACEY HANLON, PHD, A POSTDOCTORAL RESEARCHER IN THE HAWLEY LAB, WAS AWARDED A TWO-YEAR GRANT FROM THE NIH EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT 9. JOSEPH VARBERG, PHD, A POSTDOCTORAL RESEARCHER IN THE JASPERSEN LAB, RECEIVED A ONE-YEAR NIH NRSA POSTDOCTORAL FELLOWSHIP
10. JIANZHENG WU, A UNIVERSITY OF KANSAS MEDICAL CENTER PREDOCTORAL	RESEARCHER IN THE HALFMANN LAB, WAS AWARDED A ONE-YEAR FELLOWSHIP FROM THE UNIVERSITY OF KANSAS MEDICAL CENTER INSTITUTE FOR NEUROLOGICAL DISCOVERIES INDEPENDENT RESEARCH PROGRAM LEADERS LABORATORIES INDIVIDUAL SCIENTISTS AT THE SIMR SPECIALIZE IN THE STUDY OF ONE OR MORE PARTICULAR GENES, PROTEINS, OR OTHER MOLECULES, EACH OF WHICH MAY CAUSE OR INFLUENCE VARIOUS KINDS OF DISEASE. A COMPREHENSIVE LIST OF RESEARCH LEADERS FOLLOWS: 1. ALEJANDRO SNCHEZ ALVARADO, PHD, SCIENTIFIC DIRECTOR, INVESTIGATOR, AND HOWARD HUGHES MEDICAL INSTITUTE INVESTIGATOR, JOINED SIMR IN 2011 FROM THE UNIVERSITY OF UTAH'S SCHOOL OF MEDICINE, WHERE HE HELD THE H.A. & EDNA BENNING PROFESSORSHIP OF NEUROBIOLOGY AND ANATOMY. HE RECEIVED A BS IN MOLECULAR BIOLOGY AND CHEMISTRY FROM VANDERBILT UNIVERSITY IN NASHVILLE, TENN., AND A PHD IN PHARMACOLOGY AND CELL BIOPHYSICS FROM THE UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE IN CINCINNATI, OHIO. RESEARCH FOCUS: THE MOLECULAR AND CELLULAR MECHANISMS UNDERPINNING ANIMAL REGENERATION USING THE PLANARIAN SCHMIDTEA MEDITERRANEA AS A MODEL SYSTEM. 2. ARIEL BAZZINI, PHD, ASSISTANT INVESTIGATOR, JOINED SIMR IN 2016 FROM THE LAB OF ANTONIO J. GIRALDEZ, PHD, IN THE DEPARTMENT OF GENETICS AT YALE UNIVERSITY, WHERE HE COMPLETED A POSTDOCTORAL FELLOWSHIP. DR. BAZZINI RECEIVED HIS PHD IN MOLECULAR BIOLOGY AT THE UNIVERSITY OF BUENOS AIRES, ARGENTINA. FOR HIS DOCTORAL DISSERTATION, HE STUDIED PLANT GENETICS AT THE INSTITUTE OF BIOTECHNOLOGY IN ARGENTINA'S NATIONAL INSTITUTE OF AGRICULTURAL TECHNOLOGY (INTA). RESEARCH FOCUS: THE REGULATION OF GENE EXPRESSION IN VERTEBRATES. 3. JOAN CONAWAY, PHD, INVESTIGATOR, JOINED SIMR IN 2001 FROM THE OKLAHOMA MEDICAL RESEARCH FOUNDATION WHERE SHE WAS AN ASSOCIATE INVESTIGATOR OF THE HOWARD HUGHES MEDICAL INSTITUTE AND INTERIM HEAD OF THE PROGRAM IN MOLECULAR AND CELL BIOLOGY. DR. CONAWAY RECEIVED HER DOCTORATE IN CELL BIOLOGY FROM STANFORD UNIVERSITY SCHOOL OF MEDICINE. RESEARCH FOCUS: ANALYSIS OF THE MOLECULAR MECHANISM AND REGULATION OF GENE TRANSCRIPTION. 4. RONALD CONAWAY, PHD, INVESTIGATOR, JOINED SIMR IN 2001 FROM THE OKLAHOMA MEDICAL RESEARCH FOUNDATION WHERE HE WAS HOLDER OF THE CHAPMAN CHAIR IN MEDICAL RESEARCH. DR. CONAWAY RECEIVED HIS PHD IN BIOCHEMISTRY FROM STANFORD UNIVERSITY SCHOOL OF MEDICINE. RESEARCH FOCUS: ANALYSIS OF THE MOLECULAR MECHANISM AND REGULATION OF GENE TRANSCRIPTION. 5. JENNIFER GERTON, PHD, INVESTIGATOR, JOINED SIMR IN 2002 FROM A POSTDOCTORAL FELLOWSHIP IN THE LABORATORY OF DR. JOSEPH DERISI IN THE DEPARTMENT OF BIOCHEMISTRY AND BIOPHYSICS AT THE UNIVERSITY OF CALIFORNIA-SAN FRANCISCO. DR. GERTON RECEIVED A PHD IN MICROBIOLOGY AND IMMUNOLOGY FROM STANFORD UNIVERSITY. RESEARCH FOCUS: GENOMIC AND GENETIC ANALYSIS OF CHROMOSOME SEGREGATION AND CHROMOSOME DYNAMICS. 6. MATTHEW GIBSON, PHD, INVESTIGATOR AND DEAN OF THE GRADUATE SCHOOL, JOINED SIMR IN 2006 FROM A JANE COFFIN CHILDS MEMORIAL FUND POSTDOCTORAL FELLOWSHIP WITH DR. NORBERT PERRIMON AT HARVARD MEDICAL SCHOOL. DR. GIBSON RECEIVED A PHD IN ZOOLOGY FROM THE UNIVERSITY OF WASHINGTON. RESEARCH FOCUS: GENETIC ANALYSIS OF MECHANISMS CONTROLLING SIGNAL TRANSDUCTION, CELL PROLIFERATION, AND EPITHELIAL MORPHOGENESIS DURING DROSOPHILA DEVELOPMENT. 7. RANDAL HALFMANN, PHD, ASSISTANT INVESTIGATOR, JOINED SIMR IN 2015 FROM THE UNIVERSITY OF TEXAS (UT) SOUTHWESTERN MEDICAL CENTER. HE RECEIVED A PHD IN BIOLOGY FROM THE MASSACHUSETTS INSTITUTE OF TECHNOLOGY, WHERE HE WAS A NATIONAL SCIENCE FOUNDATION PREDOCTORAL FELLOW. AFTER COMPLETING HIS GRADUATE STUDIES, DR. HALFMANN OBTAINED AN INDEPENDENT POSITION AT UT SOUTHWESTERN MEDICAL CENTER WHERE HE WAS A SARA AND FRANK MCKNIGHT FELLOW AND RECEIVED A DIRECTOR'S EARLY INDEPENDENCE AWARD FROM THE NATIONAL INSTITUTES OF HEALTH. RESEARCH FOCUS: CELLULAR AND EVOLUTIONARY IMPLICATIONS OF PROTEIN SELF-ASSEMBLY USING GENETIC, BIOCHEMICAL, AND CELL-BIOLOGICAL APPROACHES. 8. R. SCOTT HAWLEY, PHD, INVESTIGATOR AND DEAN EMERITUS OF THE GRADUATE SCHOOL, JOINED SIMR IN 2001 FROM THE UNIVERSITY OF CALIFORNIA-DAVIS WHERE HE WAS A PROFESSOR OF GENETICS IN THE MOLECULAR AND CELLULAR BIOLOGY SECTION. DR. HAWLEY EARNED A PHD IN GENETICS FROM THE UNIVERSITY OF WASHINGTON AND COMPLETED POSTDOCTORAL TRAINING AS A HELEN HAY WHITNEY FELLOW AT THE INSTITUTE FOR CANCER RESEARCH IN PHILADELPHIA. RESEARCH FOCUS: INVESTIGATION OF MECHANISMS THAT INFLUENCE HOW CHROMOSOMES PAIR AND SEGREGATE DURING MEIOSIS USING DROSOPHILA AS AN EXPERIMENTAL SYSTEM. 9. SUE JASPERSEN, PHD, ASSOCIATE INVESTIGATOR, JOINED SIMR IN 2005 FROM THE LABORATORY OF DR. MARK WINEY AT THE UNIVERSITY OF COLORADO-BOULDER WHERE SHE WAS A KECK FOUNDATION FELLOW, A HELEN HAY WHITNEY FELLOW, AND THE RECIPIENT OF A LEUKEMIA & LYMPHOMA SOCIETY CAREER DEVELOPMENT AWARD. DR. JASPERSEN HOLDS A PHD IN BIOCHEMISTRY FROM THE UNIVERSITY OF CALIFORNIA-SAN FRANCISCO. RESEARCH FOCUS: INNER NUCLEAR MEMBRANE PROTEIN LOCALIZATION AND ROLE IN CHROMOSOME POSITIONING AND SEGREGATION. 10. ROBERT KRUMLAUF, PHD, SCIENTIFIC DIRECTOR EMERITUS AND INVESTIGATOR, JOINED THE SIMR IN 2000 FROM ENGLAND'S NATIONAL INSTITUTE FOR MEDICAL RESEARCH, THE RIDGEWAY, MILL HILL, LONDON, WHERE HE WAS HEAD OF THE DIVISION OF DEVELOPMENTAL NEUROBIOLOGY. DR. KRUMLAUF RECEIVED A PHD IN DEVELOPMENTAL BIOLOGY FROM OHIO STATE UNIVERSITY. RESEARCH FOCUS: ANALYSIS OF MOLECULAR PATHWAYS THAT REGULATE HOW THE MAMMALIAN HEAD, BRAIN AND NERVOUS SYSTEM ARE BUILT, USING A VARIETY OF VERTEBRATE MODEL SYSTEMS. 11. LINHENG LI, PHD, INVESTIGATOR, JOINED SIMR IN 2000 FROM THE UNIVERSITY OF WASHINGTON MEDICAL CENTER WHERE HE HELD A FACULTY APPOINTMENT AFTER COMPLETING POSTDOCTORAL TRAINING IN THE LABORATORY DIRECTED BY DR. LEROY HOOD. DR. LI EARNED HIS PHD IN MOLECULAR AND CELLULAR BIOLOGY FROM NEW YORK UNIVERSITY MEDICAL SCHOOL UNDER THE MENTORING OF DR. EDWARD ZIFF. RESEARCH FOCUS: INVESTIGATION OF MOLECULAR AND GENETIC PATHWAYS CONTROLLING ADULT STEM CELL DEVELOPMENT IN THE HEMATOPOIETIC AND INTESTINAL SYSTEMS USING TRANSGENIC AND GENE TARGETING ANIMAL MODEL APPROACHES. 12. TATJANA PIOTROWSKI, PHD, INVESTIGATOR, JOINED SIMR IN 2011 FROM THE UNIVERSITY OF UTAH'S SCHOOL OF MEDICINE, WHERE SHE WAS AN ASSOCIATE PROFESSOR IN THE DEPARTMENT OF NEUROBIOLOGY AND ANATOMY. SHE RECEIVED HER MASTER'S DEGREE FROM THE UNIVERSITY OF TUBINGEN, GERMANY, AND HER DOCTORATE DEGREE FROM THE MAX PLANCK INSTITUTE FOR DEVELOPMENTAL BIOLOGY IN TUBINGEN. RESEARCH FOCUS: COLLECTIVE CELL MIGRATION, CELL TYPE SPECIFICATION AND STEM CELL BIOLOGY IN ZEBRAFISH AS A MODEL SYSTEM. 13. NICOLAS ROHNER, PHD, ASSISTANT INVESTIGATOR, JOINED SIMR IN 2015 FROM HARVARD MEDICAL SCHOOL, WHERE HE WAS A POSTDOCTORAL FELLOW IN DR. CLIFF TABIN'S LABORATORY. HE EARNED A PHD IN BIOLOGY FROM THE MAX PLANCK INSTITUTE FOR DEVELOPMENTAL BIOLOGY IN TUBINGEN, GERMANY. RESEARCH FOCUS: GENETIC MECHANISMS AND MUTATIONS THAT UNDERLIE THE ANIMAL KINGDOM'S TREMENDOUS DIVERSITY IN MORPHOLOGY, PHYSIOLOGY, AND BEHAVIOR. 14. KAUSIK SI, PHD, ASSOCIATE SCIENTIFIC DIRECTOR AND INVESTIGATOR, JOINED SIMR IN 2005FROM THE LABORATORY OF DR. ERIC KANDEL AT COLUMBIA UNIVERSITY CENTER FOR NEUROBIOLOGY AND BEHAVIOR WHERE HE WAS A JANE COFFIN CHILDS FELLOW AND A FRANCIS GOELET FELLOW IN NEUROSCIENCE. DR. SI EARNED A PHD IN MOLECULAR BIOLOGY FROM THE ALBERT EINSTEIN COLLEGE OF MEDICINE. RESEARCH FOCUS: ROLE OF SYNAPTIC PROTEIN SYNTHESIS IN INFORMATION ACQUISITION AND MEMORY STORAGE. 15. PAUL TRAINOR, PHD, INVESTIGATOR, JOINED SIMR IN 2001 FROM A RESEARCH POSITION AT THE NATIONAL INSTITUTE FOR MEDICAL RESEARCH AT MILL HILL, LONDON, WHERE HE COMPLETED POSTDOCTORAL TRAINING. DR. TRAINOR HAS A PHD IN DEVELOPMENTAL BIOLOGY FROM CHILDREN'S MEDICAL RESEARCH INSTITUTE AT THE UNIVERSITY OF SYDNEY, AUSTRALIA. RESEARCH FOCUS: INVESTIGATION OF THE INTERACTIONS BETWEEN DISTINCT TISSUES IN THE BODY AND THEIR REGULATION DURING NORMAL DEVELOPMENT TO REVEAL PATHWAYS THAT REGULATE NORMAL CRANIAL AND FACIAL DEVELOPMENT. 16. JERRY WORKMAN, PHD, INVESTIGATOR, JOINED SIMR IN 2003 FROM THE PENNSYLVANIA STATE UNIVERSITY WHERE HE HELD THE PAUL BERG PROFESSORSHIP OF BIOCHEMISTRY AND WAS AN ASSOCIATE INVESTIGATOR OF THE HOWARD HUGHES MEDICAL INSTITUTE. DR. WORKMAN EARNED A PHD IN CELL AND MOLECULAR BIOLOGY FROM THE UNIVERSITY OF MICHIGAN AND COMPLETED POSTDOCTORAL TRAINING AT THE ROCKEFELLER UNIVERSITY WITH DR. BOB ROEDER. RESEARCH FOCUS: STUDY OF THE PROTEIN COMPLEXES THAT MODIFY CHROMATIN. 17. TING XIE, PHD, INVESTIGATOR, JOINED SIMR IN 2000 AFTER COMPLETING A HOWARD HUGHES MEDICAL INSTITUTE POSTDOCTORAL FELLOWSHIP IN THE LABORATORY OF DR. ALLAN C. SPRADLING AT THE CARNEGIE INSTITUTION OF WASHINGTON. DR. XIE RECEIVED HIS PHD FROM THE JOINT GRADUATE PROGRAM IN MOLECULAR BIOLOGY AND BIOCHEMISTRY OF RUTGERS UNIVERSITY AND THE UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY. RESEARCH FOCUS: GENETIC AND MOLECULAR ANALYSIS OF STEM CELLS AND GERM CELL DEVELOPMENT IN DROSOPHILA AND MOUSE.
18. C. RON YU, PHD, INVESTIGATOR, JOINED SIMR IN 2005 FROM THE LABORATORY	OF DR. RICHARD AXEL AT COLUMBIA UNIVERSITY CENTER FOR NEUROBIOLOGY AND BEHAVIOR WHERE HE HELD A NATIONAL INSTITUTES OF HEALTH MENTORED RESEARCH SCIENTIST AWARD FROM THE NATIONAL INSTITUTE OF MENTAL HEALTH. DR. YU EARNED HIS PHD IN MOLECULAR, CELLULAR, AND BIOPHYSICAL STUDIES AT COLUMBIA UNIVERSITY. RESEARCH FOCUS: HOW OLFACTORY SENSORY INFORMATION IS DETECTED, INTEGRATED, AND PROCESSED IN THE BRAIN TO INFLUENCE SPECIFIC INNATE BEHAVIORS. 19. SARAH ZANDERS, PHD, ASSISTANT INVESTIGATOR AND VICE DEAN OF THE GRADUATE SCHOOL, JOINED SIMR IN 2016 AFTER COMPLETION OF HER POSTDOCTORAL TRAINING IN BASIC SCIENCES AT THE FRED HUTCHINSON CANCER RESEARCH CENTER (FHCRC) WITH SUPPORT FROM A PATHWAY TO INDEPENDENCE AWARD FROM THE NATIONAL INSTITUTES OF HEALTH. FHCRC FACULTY MEMBERS HARMIT S. MALIK, PHD, AND GERRY SMITH, PHD, ADVISED HER RESEARCH ON FERTILITY, GENOME EVOLUTION, AND THE ORIGIN OF NEW SPECIES. DR. ZANDERS RECEIVED HER PHD IN GENETICS AND DEVELOPMENT FROM CORNELL UNIVERSITY. RESEARCH FOCUS: THE EFFECTS OF GENETIC CONFLICTS CAUSED BY SELFISH GENES THAT ARE EMBEDDED IN EUKARYOTIC GENOMES. 20. JULIA ZEITLINGER, PHD, INVESTIGATOR, JOINED SIMR IN 2007 FROM THE LAB OF DR. RICHARD YOUNG AT THE WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH AT MASSACHUSETTS INSTITUTE OF TECHNOLOGY WHERE SHE WAS THE RECIPIENT OF A LONG-TERM POSTDOCTORAL FELLOWSHIP FROM THE HUMAN FRONTIER SCIENCE PROGRAM. DR. ZEITLINGER EARNED A PHD IN MOLECULAR BIOLOGY FROM THE EUROPEAN MOLECULAR BIOLOGY LABORATORY IN HEIDELBERG, GERMANY. RESEARCH FOCUS: ANALYSIS OF THE GENE REGULATORY NETWORKS UNDERLYING CELLULAR DIFFERENTIATION. TECHNOLOGY CENTERS 1. PAUL KULESA, PHD, DIRECTOR OF IMAGING, JOINED SIMR IN 2002 AFTER COMPLETING A BURROUGHS WELLCOME FUND POSTDOCTORAL FELLOWSHIP IN THE LABORATORY OF DR. SCOTT E. FRASER AT THE CALIFORNIA INSTITUTE OF TECHNOLOGY. DR. KULESA RECEIVED A PHD IN APPLIED MATHEMATICS UNDER DR. J.D. MURRAY AT THE UNIVERSITY OF WASHINGTON. RESEARCH FOCUS: CELL MIGRATION IN DEVELOPMENT AND CANCER. 2. MICHAEL WASHBURN, PHD, DIRECTOR OF PROTEOMICS, JOINED SIMR IN 2003 FROM THE TORREY MESA RESEARCH INSTITUTE IN SAN DIEGO WHERE HE WAS A SENIOR STAFF SCIENTIST IN PROTEOMICS. HE EARNED A PHD IN BIOCHEMISTRY AND ENVIRONMENTAL TOXICOLOGY FROM MICHIGAN STATE UNIVERSITY BEFORE COMPLETING A POSTDOCTORAL FELLOWSHIP WITH PROFESSOR JOHN YATES, III IN THE DEPARTMENT OF MOLECULAR BIOTECHNOLOGY AT THE UNIVERSITY OF WASHINGTON. RESEARCH FOCUS: QUANTITATIVE PROTEOMICS AND PROTEIN COMPLEX DYNAMICS.

For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ.

Cat. No. 51056K

Schedule O (Form 990 or 990-EZ) 2019

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE R
(Form 990)

Department of the Treasury
Internal Revenue Service

Related Organizations and Unrelated Partnerships

Complete if the organization answered "Yes" on Form 990, Part IV, line 33, 34, 35b, 36, or 37.
MediumBullet

Attach to Form 990.
MediumBullet

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2019

Open to Public Inspection

Name of the organization

STOWERS INSTITUTE FOR MEDICAL RESEARCH

Employer identification number

20-2993509

Part I

Identification of Disregarded Entities. Complete if the organization answered "Yes" on Form 990, Part IV, line 33.

(a) Name, address, and EIN (if applicable) of disregarded entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Total income	(e) End-of-year assets	(f) Direct controlling entity

Part II

Identification of Related Tax-Exempt Organizations. Complete if the organization answered "Yes" on Form 990, Part IV, line 34 because it had one or more related tax-exempt organizations during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Exempt Code section	(e) Public charity status (if section 501(c)(3))	(f) Direct controlling entity	(g) Section 512(b)(13) controlled entity?
(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Exempt Code section	(e) Public charity status (if section 501(c)(3))	(f) Direct controlling entity	Yes	No
(1)STOWERS SCIENTIFIC EDUCATION INSTITUTE 1000 EAST 50TH STREET KANSAS CITY,MO64110 20-5916445	SUPPORT ORG	DE	501(C)(3)	12A, I	SIMR	Yes
(2)STOWERS RESOURCE MANAGEMENTINC 1000 EAST 50TH STREET KANSAS CITY,MO64110 41-2186719	SUPPORT ORG	DE	501(C)(3)	12A, I	SIMR	Yes
(3)BIOMED VALLEY CORPORATION 1000 EAST 50TH STREET KANSAS CITY,MO64110 74-3238244	SUPPORT ORG	DE	501(C)(3)	12A, I	SIMR	Yes
(4)STOWERS REAL ESTATE HOLDING CORPORATION 1000 EAST 50TH STREET KANSAS CITY,MO64110 26-1472230	TITLE HOLDING	DE	501(C)(2)	N/A	SRM	Yes
(5)STOWERS POLICY INSTITUTE INC 100O EAST 50TH STREET KANSAS CITY,MO64110 20-3270502	SEE PART VII	DE	501(C)(4)	N/A	SIMR	Yes
(6)THE GRADUATE SCHOOL OF SIMR 1000 EAST 50TH STREET KANSAS CITY,MO64110 46-4588696	EDUCATION	MO	501(C)(3)	2	SIMR	Yes

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50135Y

Schedule R (Form 990) 2019

Page 2

Part III

Identification of Related Organizations Taxable as a Partnership. Complete if the organization answered "Yes" on Form 990, Part IV, line 34, because it had one or more related organizations treated as a partnership during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(f) Share of total income	(g) Share of end-of-year assets	(h) Disproprtionate allocations?		(i) Code V-UBI amount in box 20 of Schedule K-1 (Form 1065)	(j) General or managing partner?
(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(f) Share of total income	(g) Share of end-of-year assets	Yes	No	(i) Code V-UBI amount in box 20 of Schedule K-1 (Form 1065)	Yes	No

Part IV

Identification of Related Organizations Taxable as a Corporation or Trust. Complete if the organization answered "Yes" on Form 990, Part IV, line 34 because it had one or more related organizations treated as a corporation or trust during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(e) Type of entity (C corp, S corp, or trust)	(f) Share of total income	(g) Share of end-of-year assets	(i) Section 512(b)(13) controlled entity?
(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(e) Type of entity (C corp, S corp, or trust)	(f) Share of total income	(g) Share of end-of-year assets	Yes	No
(1) BIOMED VALLEY DISCOVERIESINC 1000 EAST 50TH STREET KANSAS CITY,MO64110 06-1646533	SEE PART VII	DE	BVC	C CORP	0	0	Yes

Schedule R (Form 990) 2019

Page 3

Part V

Transactions With Related Organizations. Complete if the organization answered "Yes" on Form 990, Part IV, line 34, 35b, or 36.

Note. Complete line 1 if any entity is listed in Parts II, III, or IV of this schedule.

Yes

1 During the tax year, did the orgranization engage in any of the following transactions with one or more related organizations listed in Parts II-IV?

a Receipt of (i) interest, (ii) annuities, (iii) royalties, or (iv) rent from a controlled entity .....................

Yes

b Gift, grant, or capital contribution to related organization(s) ............................

c Gift, grant, or capital contribution from related organization(s) ............................

Yes

d Loans or loan guarantees to or for related organization(s) ............................

e Loans or loan guarantees by related organization(s) ............................

f Dividends from related organization(s) ............................

g Sale of assets to related organization(s) ............................

h Purchase of assets from related organization(s) ............................

i Exchange of assets with related organization(s) ............................

j Lease of facilities, equipment, or other assets to related organization(s) .......................

Yes

k Lease of facilities, equipment, or other assets from related organization(s) ......................

Yes

l Performance of services or membership or fundraising solicitations for related organization(s) .....................

m Performance of services or membership or fundraising solicitations by related organization(s) .................

n Sharing of facilities, equipment, mailing lists, or other assets with related organization(s) ...................

Yes

o Sharing of paid employees with related organization(s) ............................

Yes

p Reimbursement paid to related organization(s) for expenses ............................

Yes

q Reimbursement paid by related organization(s) for expenses ............................

Yes

r Other transfer of cash or property to related organization(s) ............................

Yes

s Other transfer of cash or property from related organization(s) ............................

If the answer to any of the above is "Yes," see the instructions for information on who must complete this line, including covered relationships and transaction thresholds.

(a) Name of related organization	(b) Transaction type (a-s)	(c) Amount involved	(d) Method of determining amount involved
(1) BIOMED VALLEY DISCOVERIES INC	A	755,726	MARKET VALUE
(2) BIOMED VALLEY DISCOVERIES INC	A	15,304	MARKET VALUE
(3) STOWERS RESOURCE MANAGEMENT INC	C	63,000,000	MARKET VALUE
(4) STOWERS REAL ESTATE HOLDING CORP	K	2,230,551	MARKET VALUE
(5) STOWERS RESOURCE MANAGEMENT INC	P	26,810,693	COST REIMB.
(6) THE GRADUATE SCHOOL OF SIMR	P	1,217,267	COST REIMB.
(7) BIOMED VALLEY DISCOVERIES INC	P	342,202	COST REIMB.
(8) BIOMED VALLEY DISCOVERIES INC	Q	429,034	COST REIMB.
(9) THE GRADUATE SCHOOL OF SIMR	R	1,285,700	MARKET VALUE
(10) SEE PART VII FOR ADDITIONAL INFORMATION

Schedule R (Form 990) 2019

Page 4

Part VI

Unrelated Organizations Taxable as a Partnership. Complete if the organization answered "Yes" on Form 990, Part IV, line 37.

Provide the following information for each entity taxed as a partnership through which the organization conducted more than five percent of its activities (measured by total assets or gross revenue) that was not a related organization. See instructions regarding exclusion for certain investment partnerships.

(a) Name, address, and EIN of entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(e) Are all partners section 501(c)(3) organizations?		(f) Share of total income	(g) Share of end-of-year assets	(h) Disproprtionate allocations?		(i) Code V-UBI amount in box 20 of Schedule K-1 (Form 1065)	(j) General or managing partner?
(a) Name, address, and EIN of entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	Yes	No	(f) Share of total income	(g) Share of end-of-year assets	Yes	No	(i) Code V-UBI amount in box 20 of Schedule K-1 (Form 1065)	Yes	No

Schedule R (Form 990) 2019

Page 5

Part VII

Supplemental Information

Provide additional information for responses to questions on Schedule R. (see instructions).

Return Reference	Explanation
PART II, LINE (5), COLUMN B:	STOWERS POLICY INSTITUTE INC'S. ("SPI") PRIMARY ACTIVITY IS TO PROMOTE INNOVATIVE AND ETHICAL BIOMEDICAL RESEARCH, THERAPIES AND CURES, AND TO ADVOCATE FOR A POLITICAL, ECONOMIC AND SOCIAL ENVIRONMENT THAT ADVANCES, FACILITIES, AND PROTECTS THAT RESEARCH AND THOSE THERAPIES AND CURES.
PART IV, LINE (1), COLUMN B:	BIOMED VALLEY DISCOVERIES, INC.'S ("BVD") PRIMARY ACTIVITY IS THE DEVELOPMENT AND MARKETING OF SCIENTIFIC DISCOVERIES. BIOMED VALLEY CORPORATION ("BVC") IS THE 100% OWNER OF BVD STOCK.
PART V, LINE 2 (1) BVD:	SIMR RECEIVES ROYALTY PAYMENTS FROM BVD PURSUANT TO A LICENSED TECHNOLOGY AGREEMENT DATED JANUARY 29, 2006. THESE ROYALTY PAYMENTS DO NOT CONSTITUTE GROSS INCOME DERIVED FROM AN UNRELATED TRADE OR BUSINESS UNDER SECTION 512(B)(13). THE ROYALTY PAYMENTS FROM BVD TO SIMR DO NOT REDUCE BVD'S TAXABLE INCOME, WHICH WOULD HAVE BEEN UNRELATED BUSINESS INCOME IF BVD WERE EXEMPT UNDER SECTION 501(C)(3) AND HAD THE SAME EXEMPT PURPOSE AS SIMR. IN ADDITION, THE SPECIAL RULE UNDER 512(B)(13)(E) APPLIES.
PART V, LINE 2 (2) BVD:	TYPE A, SIMR RECEIVES SUBLEASE PAYMENTS FROM BVD BASED ON COST FOR LESS THAN 300 SQ FT OF SPACE FOR A LIMITED USE PURPOSE. THE RENT PAYMENTS FROM BVD TO SIMR DO NOT REDUCE BVD'S TAXABLE INCOME WHICH WOULD HAVE BEEN UBTI IF BVD WERE EXEMPT UNDER 501(C)(3) AND HAD THE SAME EXEMPT PURPOSE AS SIMR. THEREFORE, NO PORTION OF THE RENT PAYMENTS FROM BVD CONSTITUTES UNRELATED BUSINESS INCOME TO SIMR UNDER SECTION 512(B)(13).
PART V, LINE 2 (3) SRM:	TYPE C, SRM PROVIDED FINANCIAL SUPPORT TO SIMR TO BE USED BY SIMR IN FURTHERANCE OF SIMR'S EXEMPT PURPOSE OF CONDUCTING MEDICAL RESEARCH.
PART V, LINE 2, (4) SREHC	TYPE K, SIMR ENTERED INTO A LEASE EFFECTIVE JANUARY 1, 2009 WITH SREHC, A 501(C)(2) TAX EXEMPT ORGANIZATION THAT IS A RELATED PARTY TO SIMR. THE LEASE HAS AN ORIGINAL TERM OF 10 YEARS WITH A PROVISION FOR ADDITIONAL OPTION YEARS FOR A 280,000 SQUARE FEET BUILDING. REFLECTS SIMR'S LEASE PAYMENTS TO SREHC IN 2019.
PART V, LINE 2, (5) SRM	TYPE P, SIMR REIMBURSED SRM FOR COSTS ASSOCIATED WITH SRM'S ADMINISTRATIVE AND SUPPORT SERVICES PROVIDED TO SIMR. SRM IS A SUPPORTING ORGANIZATION TO SIMR.
PART V, LINE 2, (6) GSSIMR	TYPE P, SIMR REIMBURSED GSSIMR FOR CERTAIN STUDENT EXPENSES INCURRED DURING TIME SPENT IN SIMR LABS.
PART V, LINE 2, (7) BVD	TYPE P, SIMR REIMBURSED BVD FOR SERVICES ON THE SERVICE COST METHOD.
PART V, LINE 2, (8) BVD	TYPE Q, BVD REIMBURSED SIMR FOR SERVICES ON THE SERVICE COST METHOD.
PART V, LINE 2, (9) GSSIMR	TYPE R, EACH ACADEMIC YEAR, SIMR PROVIDES GSSIMR WITH AN APPROPRIATION BASED ON A PER CAPITA FUNDING FORMULA RELATED TO THE NUMBER OF ACTIVELY ENROLLED PREDOCTORAL RESEARCHERS AT GSSIMR.
PART V, LINE 2, (10):	ALL OTHER TRANSACTIONS FOR LINE 1 WERE BETWEEN 501(C)(3) PUBLIC CHARITIES AND BELOW REPORTING THRESHOLDS.

Schedule R (Form 990) 2019

Additional Data

Software ID:
Software Version:

1	Briefly describe the organization’s mission or most significant activities: SIMR'S EXEMPT PURPOSE IS TO PERFORM MEDICAL RESEARCH IN THE PUBLIC INTEREST WITH THE GOAL OF EXPANDING OUR UNDERSTANDING OF THE FUNDAMENTAL PROCESSES OF LIVING CELLS.
2	Check this box
3	Number of voting members of the governing body (Part VI, line 1a) ........	3	8
4	Number of independent voting members of the governing body (Part VI, line 1b) .....	4	3
5	Total number of individuals employed in calendar year 2019 (Part V, line 2a) ......	5	374
6	Total number of volunteers (estimate if necessary) .............	6	3
7a	Total unrelated business revenue from Part VIII, column (C), line 12 ........	7a	0
b	Net unrelated business taxable income from Form 990-T, line 39 .........	7b

		Prior Year	Current Year
8	Contributions and grants (Part VIII, line 1h) .........	85,419,816	69,501,308
9	Program service revenue (Part VIII, line 2g) .........	256,571	174,675
10	Investment income (Part VIII, column (A), lines 3, 4, and 7d ) ....	739,516	2,937,748
11	Other revenue (Part VIII, column (A), lines 5, 6d, 8c, 9c, 10c, and 11e)	108,655	835,747
12	Total revenue—add lines 8 through 11 (must equal Part VIII, column (A), line 12)	86,524,558	73,449,478
13	Grants and similar amounts paid (Part IX, column (A), lines 1–3 )...	975,000	0
14	Benefits paid to or for members (Part IX, column (A), line 4).....	0	0
15	Salaries, other compensation, employee benefits (Part IX, column (A), lines 5–10)	34,934,899	36,569,659
16a	Professional fundraising fees (Part IX, column (A), line 11e) .....	0	0
b	Total fundraising expenses (Part IX, column (D), line 25) 0
17	Other expenses (Part IX, column (A), lines 11a–11d, 11f–24e)....	50,028,333	55,133,761
18	Total expenses. Add lines 13–17 (must equal Part IX, column (A), line 25)	85,938,232	91,703,420
19	Revenue less expenses. Subtract line 18 from line 12.......	586,326	-18,253,942
		Beginning of Current Year	End of Year
20	Total assets (Part X, line 16).............	335,909,539	312,071,612
21	Total liabilities (Part X, line 26).............	106,170,867	101,229,740
22	Net assets or fund balances. Subtract line 21 from line 20.....	229,738,672	210,841,872

Sign Here

	Signature of officer	Date

	Type or print name and title


4a	(Code: ) (Expenses $ 82,661,647 including grants of $ ) (Revenue $ 174,675 )
	SIMR'S ACCOMPLISHMENTS ARE DESCRIBED IN SCHEDULE O.

4b	(Code: ) (Expenses $ including grants of $ ) (Revenue $ )












4c	(Code: ) (Expenses $ including grants of $ ) (Revenue $ )












4d	Other program services (Describe in Schedule O.)
	(Expenses $ including grants of $ ) (Revenue $ )
4e	Total program service expenses82,661,647

1b	Sub-Total................
c	Total from continuation sheets to Part VII, Section A....
d	Total (add lines 1b and 1c)...........	3,802,335	6,290,167	609,277

(A) Name and business address	(B) Description of services	(C) Compensation
ETC GROUP LLC, 1997 S 1100 E SALT LAKE CITY,UT84106	SOFTWARE DEVEL SRVCS	242,840
AMERICAN CENTURY INVESTMENTS, 4500 MAIN ST KANSAS CITY,MO64111	INDIRECT - SEE SCH O	169,000



2 Total number of independent contractors (including but not limited to those listed above) who received more than $100,000 of compensation from the organization 2

1a	Federated campaigns..		1a
b	Membership dues..		1b
c	Fundraising events..		1c
d	Related organizations		1d	63,100,000
e	Government grants (contributions)		1e	5,608,271

f	All other contributions, gifts, grants, and similar amounts not included above		1f	793,037

g	Noncash contributions included in lines 1a - 1f:$		1g	63,100,000

h Total. Add lines 1a-1f.......		69,501,308

		Business Code
2a	COLLABORATION FEE FROM HHMI 501(C)(3)	900099	174,675	174,675
b
c
d
e
f	All other program service revenue.
g	Total. Add lines 2a–2f .....		174,675

3 Investment income (including dividends, interest, and othersimilar amounts) ......			1,654,052			1,654,052
4 Income from investment of tax-exempt bond proceeds			0
5 Royalties...........			775,726			775,726
		(ii) Personal	(i) Real
6a	Gross rents		15,304	6a
b	Less: rental expenses		15,304	6b
c	Rental income or (loss)	0	0	6c
d	Net rental income or (loss).......			0
		(ii) Other	(i) Securities
7a	Gross amount from sales of assets other than inventory	106,900	96,340,208	7a
b	Less: cost or other basis and sales expenses	76,781	95,086,631	7b
c	Gain or (loss)	30,119	1,253,577	7c
d	Net gain or (loss).........			1,283,696			1,283,696
8a	Gross income from fundraising events (not including $ of contributions reported on line 1c). See Part IV, line 18 ....
			8a	0
b	Less: direct expenses ...		8b	0
c	Net income or (loss) from fundraising events..			0
9a	Gross income from gaming activities. See Part IV, line 19 ...
			9a	0
b	Less: direct expenses ...		9b	0
c	Net income or (loss) from gaming activities..			0
10a	Gross sales of inventory, less returns and allowances ..
			10a	0
b	Less: cost of goods sold ..		10b	0
c	Net income or (loss) from sales of inventory..			0
Business Code			Miscellaneous Revenue
11a	OTHER REBATES & REVENUE		900099	60,021			60,021
b
c
d	All other revenue ....
e	Total. Add lines 11a–11d ......			60,021
12	Total revenue. See instructions.....			73,449,478	174,675		3,773,495

1	Grants and other assistance to domestic organizations and domestic governments. See Part IV, line 21 ....	0
2	Grants and other assistance to domestic individuals. See Part IV, line 22 ...........	0
3	Grants and other assistance to foreign organizations, foreign governments, and foreign individuals. See Part IV, lines 15 and 16. .............	0
4	Benefits paid to or for members .......	0
5	Compensation of current officers, directors, trustees, and key employees ...........	2,279,090	2,051,181	227,909	0
6	Compensation not included above, to disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B) .........	782,159	703,943	78,216	0
7	Other salaries and wages........	24,432,159	21,988,943	2,443,216	0
8	Pension plan accruals and contributions (include section 401(k) and 403(b) employer contributions) ....	2,539,143	2,285,229	253,914
9	Other employee benefits .......	4,845,937	4,361,343	484,594	0
10	Payroll taxes ...........	1,691,171	1,522,054	169,117	0
11	Fees for services (non-employees):
a	Management ......	0
b	Legal .........	0
c	Accounting ...........	0
d	Lobbying ...........	0
e	Professional fundraising services. See Part IV, line 17	0
f	Investment management fees ......	0
g	Other (If line 11g amount exceeds 10% of line 25, column (A) amount, list line 11g expenses on Schedule O)	1,166,109	1,049,498	116,611
12	Advertising and promotion ....	0
13	Office expenses .......	141,679	127,511	14,168	0
14	Information technology ......	340,358	306,322	34,036	0
15	Royalties ..	386,412	347,771	38,641	0
16	Occupancy ...........	2,215,247	1,993,722	221,525	0
17	Travel ............	891,238	802,114	89,124	0
18	Payments of travel or entertainment expenses for any federal, state, or local public officials .	0
19	Conferences, conventions, and meetings ....	697,978	628,180	69,798	0
20	Interest ...........	0
21	Payments to affiliates .......	0
22	Depreciation, depletion, and amortization ..	9,625,997	8,663,397	962,600	0
23	Insurance ...	0
24	Other expenses. Itemize expenses not covered above (List miscellaneous expenses in line 24e. If line 24e amount exceeds 10% of line 25, column (A) amount, list line 24e expenses on Schedule O.)
a	COST-SHARING W/RELATED ORG	30,443,614	27,399,253	3,044,361
b	LAB SUPPLIES	6,590,191	5,931,172	659,019
c	PER CAPITA APPROP. TO GSSIMR	1,285,700	1,285,700	0
d	NON-CAPITAL EQUIPMENT	465,867	419,280	46,587
e	All other expenses	883,371	795,034	88,337
25	Total functional expenses. Add lines 1 through 24e	91,703,420	82,661,647	9,041,773	0
26	Joint costs. Complete this line only if the organization reported in column (B) joint costs from a combined educational campaign and fundraising solicitation. Check here if following SOP 98-2 (ASC 958-720).

1	Cash–non-interest-bearing ........			0	1	0
2	Savings and temporary cash investments .........			1,897,970	2	937,906
3	Pledges and grants receivable, net ......			415,996	3	470,714
4	Accounts receivable, net .............			0	4	0
5	Loans and other payables to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons .......
				0	5	0
6	Loans and other receivables from other disqualified persons (as defined under section 4958(f)(1)), and persons described in section 4958(c)(3)(B) ...
				0	6	0
7	Notes and loans receivable, net ...........			0	7	0
8	Inventories for sale or use ............			2,287	8	2,627
9	Prepaid expenses and deferred charges ......			330,173	9	375,470
10a	Land, buildings, and equipment: cost or other basis. Complete Part VI of Schedule D	10a	333,055,015
b	Less: accumulated depreciation	10b	194,728,136	141,078,865	10c	138,326,879
11	Investments—publicly traded securities .			101,356,319	11	85,997,459
12	Investments—other securities. See Part IV, line 11 .....			373,601	12	448,431
13	Investments—program-related. See Part IV, line 11 ..			0	13	0
14	Intangible assets ...............			0	14	0
15	Other assets. See Part IV, line 11 ...........			90,454,328	15	85,512,126
16	Total assets. Add lines 1 through 15 (must equal line 33)...			335,909,539	16	312,071,612

17	Accounts payable and accrued expenses .....	7,568,381	17	9,773,789
18	Grants payable ...	0	18	0
19	Deferred revenue .........	202,716	19	334,266
20	Tax-exempt bond liabilities .........	0	20	0
21	Escrow or custodial account liability. Complete Part IV of Schedule D	0	21	0
22	Loans and other payables to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons .........
		0	22	0
23	Secured mortgages and notes payable to unrelated third parties ..	0	23	0
24	Unsecured notes and loans payable to unrelated third parties ..	0	24	0
25	Other liabilities (including federal income tax, payables to related third parties, and other liabilities not included on lines 17 - 24). Complete Part X of Schedule D	98,399,770	25	91,121,685
26	Total liabilities. Add lines 17 through 25..	106,170,867	26	101,229,740

	Organizations that follow FASB ASC 958, check here and complete lines 27, 28, 32, and 33.
27	Net assets without donor restrictions ..........	229,617,951	27	210,635,494
28	Net assets with donor restrictions ...........	120,721	28	206,378
	Organizations that do not follow FASB ASC 958, check here and complete lines 29 through 33.
29	Capital stock or trust principal, or current funds .....		29
30	Paid-in or capital surplus, or land, building or equipment fund ...		30
31	Retained earnings, endowment, accumulated income, or other funds		31
32	Total net assets or fund balances ...........	229,738,672	32	210,841,872
33	Total liabilities and net assets/fund balances ........	335,909,539	33	312,071,612